Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

Stefania Crisci1, Raffaele Di Francia1*, Sara Mele1, Pasquale Vitale1, Giuseppina Ronga1, Rosaria De Filippi2, Massimiliano Berretta3, Paola Rossi4 and Antonio Pinto1

1 Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione “G. Pascale” IRCCS, Naples, Italy, 2 Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy, 3 Department of Medical Oncology, CRO National Cancer Institute, Aviano, Italy, 4 Department of Biology and Biotechnology “L. Spallanzani,” University of Pavia, Pavia, Italy

The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) for targeted therapy in hematology. This review focuses on the efficacy results of the currently available targeted agents and recaps the main ongoing trials in the setting of mature B-Cell non-Hodgkin lymphomas. The objective is to summarize the different classes of novel agents approved for mature B-cell lymphomas, to describe in synopsis tables the results they achieved and, finally, to draw future scenarios as we glimpse through the ongoing clinical trials. Characteristics and therapeutic efficacy are summarized for the currently approved mAbs [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs i.e., inhibitors of B-cell receptor signaling, proteasome, mTOR BCL-2 HDAC pathways. The biological disease profiling of B-cell lymphoma subtypes may foster the discovery of innovative drug strategies for improving survival outcome in lymphoid neoplasms, as well as the trade-offs between efficacy and toxicity. The hope for clinical advantages should carefully be coupled with mindful awareness of the potential pitfalls and the occurrence of uneven, sometimes severe, toxicities.

Keywords: anticancer mAbs, tyrosine kinase inhibitors, tailored therapy, personalized medicine, NHL

INTRODUCTION

Non-Hodgkin lymphomas (NHL) encompass malignant tumors of the lymphoid tissues variously resulting from the clonal growth of B cells, T cells, natural killer cells, or originators of these cells. They derive from cells at varying stages of maturation, and many of the biologic features of these malignant cells reflect their normal counterparts. B cell lymphomas may arise at any stage of normal B cell development, but most are derived from cells that have been exposed to the germinal center reaction (1). The recent World Health Organization (WHO) classification categorizes B-cell lymphomas by morphology, immunophenotype, and genetic findings. These
histological subtypes of B-cell lymphomas recognized by the WHO present different and somehow specific profiles of clinical aggressiveness and prognosis. Despite, the WHO classification does not explicitly order B-cell lymphomas on the basis of their aggressiveness, also given the significant patient-to-patient variability in the natural history of these neoplasms. Both in real life practice and in the vast majority of clinical trials histological subtypes have been roughly segregated into indolent, aggressive and very aggressive groups, according to their usual clinical behavior. Indolent B-cell lymphomas represent 35 to 40 percent of the non-Hodgkin lymphomas (NHL), and survival is generally measured in years. The most common subtypes include follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a fraction of mantle cell lymphoma (MCL) cases, extramedullary, nodal and splenic marginal zone lymphoma (MZL), and lymphoplasmacytic lymphoma (LPL) (1, 2). Aggressive subtypes if left untreated survive a few months but if adequately treated may achieve definitive remissions and cure in a significant fraction of patients. The most common subtypes are large B-cell lymphomas, including anaplastic and primary mediastinal lymphoma, and various kinds of diffuse large B cell lymphoma (DLBCL). The highly aggressive subtypes represent about 5 percent of the NHL and survival may be measured in only a few weeks if left untreated. Curing is possible if vigorously treated with high-intensity chemotherapy protocols.

Chemotherapy, radiotherapy, and immunotherapy have been used, alone or in combination, in the last decades to treat B-cell NHL. Therapeutic outcomes may vary according to clinical behavior, whether indolent or aggressive, and patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies. Dismal prognosis still affects a significant fraction of patients with mature B-cell lymphomas, and new treatment strategies should be conceived to improve both objective response and survival (3–9).

In the last decade, the remarkable and exponential change in the natural history of these neoplasms. Both in real life practice and in the vast majority of clinical trials histological subtypes have been roughly segregated into indolent, aggressive and very aggressive groups, according to their usual clinical behavior. Indolent B-cell lymphomas represent 35 to 40 percent of the non-Hodgkin lymphomas (NHL), and survival is generally measured in years. The most common subtypes include follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a fraction of mantle cell lymphoma (MCL) cases, extramedullary, nodal and splenic marginal zone lymphoma (MZL), and lymphoplasmacytic lymphoma (LPL) (1, 2). Aggressive subtypes if left untreated survive a few months but if adequately treated may achieve definitive remissions and cure in a significant fraction of patients. The most common subtypes are large B-cell lymphomas, including anaplastic and primary mediastinal lymphoma, and various kinds of diffuse large B cell lymphoma (DLBCL). The highly aggressive subtypes represent about 5 percent of the NHL and survival may be measured in only a few weeks if left untreated. Curing is possible if vigorously treated with high-intensity chemotherapy protocols.

Chemotherapy, radiotherapy, and immunotherapy have been used, alone or in combination, in the last decades to treat B-cell NHL. Therapeutic outcomes may vary according to clinical behavior, whether indolent or aggressive, and patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies. Dismal prognosis still affects a significant fraction of patients with mature B-cell lymphomas, and new treatment strategies should be conceived to improve both objective response and survival (3–9).

In the last decade, the remarkable and exponential change in the treatment paradigm (3, 8, 11, 14, 17–20). Tumor immunotherapy has undergone a new phase of development, in particular linked to the development of T-cell checkpoint inhibitors and the development of CAR T-cell therapy, a personalized treatment involving the use of genetically modified T lymphocytes to attack the cancer cells (21–24).

This review is intended to provide an overview of all Food and Drug Administration (FDA)-approved novel drugs and therapies for “targeting” mature B-cell neoplasms. Immunotherapy agent treatments [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs (i.e., inhibitors of B-cell receptor signaling, proteasome and mTOR BCL-2 HDAC pathways) are summarized in their mechanisms of action (Figure 1)—the results they achieved in mature B-cell lymphomas are described in synoptic tables and the ongoing clinical trials are detailed to draw, at a glance, a glimpse on future scenarios.

METHODS
To assess the actual understanding of targeted drugs for NHL, a search on the Cochrane Library and PubMed were performed crossing the keywords “Targeted Therapy” AND “B-Cell Neoplasm.” In the second step “indolent” and “aggressive and very aggressive” were singularly added, limited to the English literature but with no restriction on time. “Monoclonal antibodies” and “Small molecule Inhibitors” restricted the search. The authors examined the titles of the 2090 papers retrieved; 521 of them met the call for monoclonal antibodies while 183 were relevant to SMIs. Most of them were cited in the manuscript.

Papers that did not include anticancer inhibitor series and appeared redundant were excluded. A search for abstracts or full text led to the exclusion of other non-pertinent papers. For studies conducted by the same research institute at different times, the most recent and complete one was included unless different methods, endpoints, or specific issues had been addressed. Papers whose full text or at least abstract were not available were excluded as well. The reference sections of pertinent papers were searched for other relevant articles. Here, we considered novel agents to be the mAbs and SMIs that are in ongoing clinical trials or were in trials that have been completed in the last 2 years.

The Clinicaltrial.gov database was queried regarding the terms of each novel agent and therapy in combination with B-cell lymphoma.

MONOCLONAL ANTIBODIES (mAbs)
The therapeutic antibodies targeting cell surface receptors have been employed in the standard care treatments for most cancers, both solid tumors and hematological neoplasms. Therapeutic mAbs target specific antigen molecules, such as extracellular growth factors and transmembrane receptors. In some cases, mAbs are conjugated with radioisotopes or toxins to allow the specific delivery of these cytotoxic agents to the tumor cell target.
In general, the mechanisms that allow therapeutic antibodies to inhibit growth or kill cancer cells fall into two categories: immune-mediated mechanisms as antibody-dependent cell cytotoxicity (ADCC), and complementary cytotoxicity (CDC), and mechanisms that interfere with tumorigenesis pathways (e.g., triggering apoptosis, inhibiting cell proliferation or blocking of angiogenesis) (25).

Herein, for the currently approved mAbs for Lymphomas (Table 1) we recap in four groups the efficacy of (i) anti-Cluster of differentiation (CD) mAbs; (ii) immune checkpoint inhibitors; (iii) chimeric antigen receptor (CAR) T-cell therapy; and (iv) bispecific antibodies.

**Anti-CD mAbs**

In this category are the Anti-CD20 Rituximab and the anti-CD52 Alemtuzumab, the forefathers of the mAbs designed for lymphocyte blocking activities. Both are two chimeric (murine-human) antibodies. The success of rituximab has elicited interest in the development of new agents for other surface antigens on malignant B cells. A new generation of anti-CD20 mAbs, including ofatumumab, obinutuzumab, and ublituximab, has been designed with features, distinctive from rituximab, that realize an improvement of ADCC and CDC (26).

**Alemtuzumab** is an anti-CD52 antibody effective in CLL. Currently, it is only accessible on a compassionate use basis (27, 28).

**Brentuximab vedotin** (SGN-35) is a conjugated antibody consisting of a chimeric monoclonal anti-CD30 antibody linked to the strong microtubule inhibitor monomethyl auristatin E (MMAE). After CD30 binding, SGN-35 is internalized, and the MMAE is released by the action of lysosomal enzymes on the valine-citrulline linker. The antineoplastic mechanism of the brentuximab vedotin exerts is still not entirely clear. Dissemination of MMAE in the tumor microenvironment and cytotoxic effects on “spectator cells” may partly explain its action (29). On 2011, it was approved by the FDA for the treatment of Hodgkin lymphoma (HL) patients, but it may also be adopted in cases of ALK-positive large B-cell lymphoma (LBCL) and Primary Effusion LBCL (30–34).

**Camidanlumab Tesirine** (ADCT-301) is a pyrrolobenzodiazepine (PBD) Dimer-containing ADC anti-CD25 (the alpha chain of the IL-2 receptor) (35). CD25 is present...
TABLE 1 | Targeted drugs for immunotherapy and signal transduction inhibitors (SMIs) with indications for mature B-cell Lymphomas.

| Drug class | Drug (brand name) | Target | Indication |
|------------|-------------------|--------|------------|
| IMMUNOTHERAPY (mAbs and CAR-T) | | | |
| Anti-CD mAbs | Alemtuzumab (Lemtrada) | CD52 | CLL/SLL |
| Brentuximab vedotin (Adcetris) | CD30 | LBCL-ALK+, DLBCL |
| Camidanlumab Tesirine (ADC-301) | CD25 | DLBCL |
| Dacetuzumab | CD40 | B-NHL |
| Lucatumumab | CD40 | CLL/SLL |
| Obinutuzumab (Gazyva) | CD20 | B-NHL |
| Ofatumumab (Arzerra) | CD20 | FL, DLBCL, B-NHL |
| Polatuzumab Vedotin (DCDS4501A) | CD79b | FL, DLBCL, B-NHL |
| Rituximab (Mabthera) | CD20 | CLL/SLL, LPL, FL, MZL, MCL, DLBCL, HG-BCL |
| Camidanlumab Tesirine (ADC-301) | CD25 | DLBCL |
| Dacetuzumab | CD40 | B-NHL |
| Lucatumumab | CD40 | CLL/SLL |
| Obinutuzumab (Gazyva) | CD20 | B-NHL |
| Ofatumumab (Arzerra) | CD20 | FL, DLBCL, B-NHL |
| Polatuzumab Vedotin (DCDS4501A) | CD79b | FL, DLBCL, B-NHL |
| Rituximab (Mabthera) | CD20 | CLL/SLL, LPL, FL, MZL, MCL, DLBCL, HG-BCL |
| Ublituximab (TG-1101) | CD20 | B-NHL |
| Immune Checkpoint inhibitors | Atezolizumab (Tecentriq) | PD-L1 | FL, DLBCL |
| Durvalumab | PD-L1 | B-NHL, DLBCL |
| Ipilimumab (Yervoy) | CTLA-4 | B-NHL, FL |
| Nivolumab (Opdivo) | PD-1 | DLBCL, FL |
| Pembrolizumab (Keytruda) | PD-1 | DLBCL |
| Pidilizumab (MEDI4736) | PD-1 | DLBCL |
| Urelumab | CD137 | CLL/SLL |
| Chimeric Antigen receptor (CAR) T-Cell Therapy | Axicabtagene ciloleucel | CAR T-4-1BB | DLBCL |
| Tsagenlecleucel (CTL019) | CAR T-4-1BB | HG-BCL |
| Bispecific antibodies | AFM13 | CD30/CD16A | DLBCL |
| Blinatumomab (Blinycyo) | CD19/CD3 | DLBCL |
| DART | CD19/CD3 | DLBCL |
| Mosunetuzumab (BTCT4465A) | CD20/CD3 | CLL/SLL, INHL |
| SIGNAL TRANSDUCTION PATHWAY INHIBITORS | | | |
| BCR Inhibitors | Acalabrutinib (Calquence) | BTK | CLL/SLL |
| Ibrutinib (Imbruvica) | BTK | CLL/SLL, DLBCL, MCL, MZL, |
| Buparlisib (BKM120) | PI3K | DLBCL, B-NHL |
| Copanlisib (Aliqopa) | PI3K γ | DLBCL, MCL |
| Idelalisib (Zydelig) | PI3K δ | CLL/SLL, DLBCL, FL |
| Cerdulatinib (PRT062070) | SYK JAK 1-2 | FL |
| Entospletinib (GS-9973) | SYK | CLL/SLL |
| Fostamatinib (Tavalisse) | SYK | DLBCL |
| TAK659 | SYK/FLT3 | DLBCL |
| Proteasome inhibitors | Bortezomib (Velcade) | PI3 | FL, MCL, MZL, |
| Carfilzomib (Kyprolis) | PI3 | B-NHL |
| Ixazomib (Ninlaro) | PI3 20S subunit | NHL, DLBCL |
| mTor inhibitors | Everolimus (Afinitor) | PI3 | CLL/SLL, DLBCL |
| Temsirolimus (Torisel) | PI3 | DLBCL, MCL |
| BCL2 Inhibitor | Venetoclax (Venclexta) | BH3 domain | DLBCL, CLL/SLL |
| HDAC Inhibitors | CUDC-907 | Class I and II + PI3K | DLBCL |
| Mocetinostat (MGCD0103) | Class I and IV | DLBCL, FL |
| Panobinostat (Farydak) | Class I and IV | DLBCL |
| Vorinostat (Zolinza) | Class I and II | FL |

B-NHL, B-NHL not otherwise specified; CLL/SLL, Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia; DLBCL, Diffuse Large B cell Lymphoma; FL, Follicular Lymphoma; HG-BCL, High Grade B-cell lymphomas; INHL, indolent NHL; LBCL, Large B-cell lymphoma; MCL, Mantle Cell Lymphoma; MZL, Marginal Zone Lymphoma.
on the cell surface in B-cell lymphomas such as DLBCL, further than several T-cell lymphoma subtypes (36, 37).

**Dacetuzumab** is a monoclonal anti-CD40 antibody. A specific gene signature may be predictive of sensitivity to dacetuzumab in patients with DLBCL. It has shown effectiveness as monotherapy in a phase I study of 50 B-cell NHL patients. Almost 33% of patients had a reduction in tumor bulk with an 8 mg/kg/week dose for 4 weeks. In one case a complete response was observed, and five cases showed partial responses (38, 39).

**Lucatumumab** is another monoclonal anti-CD40 antibody. In relapsing CLL, results of the phase I reported that the dosages were well-tolerated in a cohort of 26 patients; 1 patient had a partial response, in 17 cases the disease was stable (40, 41).

**Obinutuzumab** is another humanized anti-CD20-IgG2 class of monoclonal antibody. It retains better ADCC than rituximab, with less CDC than ofatumumab. It has a unique feature in CD20 cross-link, resulting in increased direct cell death. FDA approved obinutuzumab for the treatment of CLL. Also, this mAB has been tested for R/R NHL. A phase III study compared alkylating agent (bendamustine) alone vs. obinutuzumab plus bendamustine followed by maintenance therapy with obinutuzumab in indolent NHL patients refractory to rituximab. The outcomes reported a significantly longer PFS in the of obinutuzumab plus bendamustine arm (24, 42).

**Ofatumumab** is a human mAB direct against a new CD20 epitope. In preclinical models compared with rituximab, ofatumumab has demonstrated a closer linkage with the B-cell surface and enhanced complement-dependent cytotoxicity (43–45).

**Polatuzumab vedotin** is a first-in-class anti-CD79b antibody-drug conjugate (ADC) currently being investigated for the treatment of different NHLs (46, 47). CD79b protein is highly specific and expressed in most of B-cell malignancies (48). To date, some ongoing studies are assessing the safety and effectiveness of polatuzumab vedotin for several types of NHL, including trials exploring combinations with obinutuzumab, rituximab, venetoclax, and atezolizumab (46, 47, 49–51).

**Rituximab** is still the most widely used antibody for treating mature B-cell lymphoma NHL B cells, also including CLL/SLL. Rituximab is an IgG1 chimeric antibody binding to CD20, a B-lymphocyte antigen transmembrane, which is present on the surface of both non-neoplastic (pre, immature, mature, and activated B cells) and malignant B cells (52, 53). The antibody was first approved in 1997 for NHL and subsequently, in 2009, for CLL. After that, rituximab has become an ordinary component of the treatment of FL, DBLCL, and MCL (25).

**Ublituximab** (TG-1101) targets an exclusive epitope on the CD20 and has been engineered to improve affinity for all variants of FcγRIIIa receptors, with better ADCC than ofatumumab and rituximab (54).

**Commonly Anti-CD mAbs Toxicities**

Due to the presence of the entire range of murine immunoglobulins (Igs), mAbs retain a high antigenic potential to humans, therefore carrying a risk for hypersensitivity reactions upon parenteral administration. Indeed, infusional reactions take place quite commonly during or after mAbs administration. Tumor lysis syndrome may occur in patients carrying an elevated number of circulating neoplastic cells. Infusion-related adverse events are equally frequent and may be severe as well, seen also with the new-generation anti-CD20 mAbs ofatumumab and obinutuzumab. The toxicity profile of the Brentuximab vedotin is manageable, though the peripheral neuropathy is an important clinical feature hampering prolonged administration of the drug (29). Patients treated with these new drugs often may form anti-mouse immunoglobulin antibodies, which could counteract the therapeutic effect. To limit these adverse effects, the more recently developed chimeric mAbs contain an increased proportion of human Ig components (about 65%) and a reduced portion of murine Ig components while humanized mAbs account for 95% of the human component (55). Their co-administration with vaccines should be avoided.

**Immune Checkpoint Inhibitors (ICIs)**

Immunotherapy has reformed the treatment of solid tumors and hematological neoplasms over the past decade with numerous agents approved by the FDA in recent years. While various approaches are used to modify the antitumor immunity of the host, perhaps the most commonly studied and used is the checkpoint block (15, 56–59). The motivation for adopting ICIs in the treatment of lymphoma relies on the existence in such malignancies of mechanisms that escape immune surveillance due to genetic variance. These agents may re-educate cells in the microenvironment, restoring chemokine and cytokine signaling as well as expression of checkpoint proteins (56, 60–66). They are able to block the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) pathways. PD-1 is an important receptor of the immune checkpoint expressed on activated T cells (67). In recent years, interest in the inhibition of PD-1 in combination with other therapies has increased in the hope of generating a synergistic anti-tumor effect. CTLA-4 is a co-inhibitory receptor expressed primarily in the cytoplasm of inactive naïve T cells. Upon antigen stimulus, CTLA-4 is mobilized to the T cell surface and binds with its ligands CD86 and CD80, causing down-regulation of T cell activation (68–71).

In lymphomas, blocking the checkpoint and harnessing the immune system as antineoplastic therapy is an active area of clinical study. Monoclonal antibodies directed against PD-1 and CTLA-4 are being designed to reduce the down-regulation of T-cell responses against malignant cells (68). Through diminished inhibitory signals, the immune response is improved and able to destroy the malignant cells. The results of the anti-PD-1/PD-L1 block are very exciting in lymphomas with 9p24.1 aberrations such as LBCL primary mediastinal (PMBCL), primary b-Cell testicular and cerebral lymphomas. Less encouraging results are reported for CLL/SLL and most of DLBCL (72). The currently used immune checkpoint inhibitors are the anti-PD-1 mAbs Nivolumab, Pembrolizumab, and Pidilizumab, the anti-PDL-1 mAbs Durvalumab, Urelumab, and Atezolizumab, and the anti-CTLA-4 mAb Ipilimumab (73).

The profile of PD-L1 expression by immunohistochemistry has been lately proposed to retain prognostic and diagnostic significance (24).
**Atezolizumab** (MPDL3280A), is a humanized IgG1 anti-PD-L1. It is sustained for use against several hematologic malignancies. Still little is known on the expression of CTLA-4 in human tissue. So far it has been reported that CD80 and CD86, physiological ligands for the expression of CTLA-4, can be observed in T-cell lymphoma patients, in the cells of the dendritic system, and in a subgroup of B-cells of the germinal center and B-immunoblasts in lymphomas (74).

**Durvalumab** (MEDI4736) is a high-affinity human IgG1 mAb that selectively inactivates PD-L1 by binding PD-1 and CD80. It has shown preliminary evidence of antitumor activity across multiple tumor types (68, 75).

**Ipilimumab** is a wholly humanized IgG1 mAb against the CTLA-4. Ipilimumab plus lenalidomide has been reported as well-tolerated after both autologous and allogeneic stem cell transplantation in a phase 2 study achieving a significant proportion of complete responses (76).

**Nivolumab**, a completely humanized IgG4 anti-PD-1 mAb, is now approved for melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma. The activity of nivolumab in lymphoid malignancies has also been widely tested (60, 61, 66, 68, 77). Patients with recurrent B-cell NHL were treated at the identical schedule with dose escalation of 1–3 mg/kg of nivolumab. Furthermore, nivolumab as a single agent is undergoing a trial in patients with FL and is currently in phase II studies (NCT02038946). Many ongoing studies also are assessing the effectiveness of nivolumab either in polychemotherapy and/or in combination with other targeted drugs such as ibrutinib (NCT2329847), ipilimumab (NCT01896999), nivolumab (NCT02253992), and indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor (NCT02327078). Combinations with ibrutinib or IDO1 are particularly striking in enhancing antitumor T-cell immune responses mechanism (68). Phase 2 trials with nivolumab in patients with DLBCL (CHECKMATE 139, NCT02038933) have mature results. No response was observed in a cohort of MCL patients who receive nivolumab (78).

**Pembrolizumab** (alias lambrolizumab) is a humanized IgG4 antagonistic anti-PD-1 mAb. The usage of IgG4 restricts Fc receptor engagement; this produces the loss of ADCC activity of PD-1- cells, thus enhancing the antitumor immune response. A correlation with a distinctive genetic signature has been described in large B-cell lymphomas also containing alterations and translocations in the number of copies (i.e., 9p24.1/PD-L1/PD-L2) (72). However, several studies on lambrolizumab, either as a single agent (NCT02576990, NCT02362997, NCT02453594, NCT02684292, NCT02535247) and/or in combination with rituximab (NCT02446457), SMIs such as ibrutinib, idelalisib, and IDO1 (NCT02332980, NCT02178722), or conventional chemotherapy (NCT02541565), are ongoing for DLBCL and PMBCL as well as FL and other B cell lymphomas with indolent behavior (56, 74, 79, 80).

**Pidilizumab** was the first humanized IgG1 mAb anti-PD-1 to be tested in lymphoid malignancies (56, 68, 74). It is noteworthy that CLL/SLL neoplastic cells show weak PD-1 expression (57), and low numbers of lymphocytes infiltrate PD-1 positive tumors (80). There is evidence of PD-L1 and 2 expressions in a subgroup of NHL, making this pathway a promising target (81).

**Urelumab** is a wholly humanized IgG4 mAb direct against CD137. CD137 (alias 4-1BB or TNFRSF9 receptor) is a member of the growth factor family receptors. CD137 is usually present on the activated T and B cells and monocytes. Although it is not part of the CTLA-4 or PD-1 pathways, its potential to immunostimulatory activities has gained an interest in the clinical development of this mAb. It has been assessed in terms of efficacy and safety in combination with nivolumab and/or rituximab against different subtypes of mature B-cell lymphomas (NCT02253992, NCT02420938) (68).

**Immune Checkpoint Inhibitors-Toxicities**

ICIs are tempting due to their moderately low toxicity profile. The Phase I study in solid tumors reported that 41% of patients treated with nivolumab had an adverse event, and, of them, only 6% were grade 3 or above. The investigators also reported that 71% of patients who received pembrolizumab had adverse events, with 9.5% grade 3 or higher. The main toxicity profile of CTLA-4 and PD-1 inhibitors is associated with its activity in boosting the immune response. Researches on solid tumors report hepatitis, pneumonia, colitis, thyroiditis, hypophysitis, and other inflammatory reactions. Patients receiving therapies with checkpoint inhibitors should regularly be checked for thyroid function and ACTH/cortisol levels if they experience symptoms such as fatigue or hyponatremia (58, 59, 74).

**Chimeric Antigen Receptor (CAR) T-Cell Therapy**

It is known that lymphomas are highly susceptible to cellular therapies, including allogeneic stem cell transplantation and the adoptive relocation of specific EBV T cells, which could be seen as the predecessor of the CAR T cells (82). CAR T cells are autologous T lymphocytes genetically modified to bind to specific antigens present on cancer cells. As a result of the binding of CAR T cells to a neoplastic cell, the signaling domains stimulate cytokine secretion, cytolysis of the tumor cell, and T cell proliferation. CAR T cells are created by apheresis of the mononuclear cells from peripheral blood. Successively, the isolated T cells are then transduced in vitro with a retroviral or lentiviral vector with a CAR complex including a single-chain variable fragment of antibodies (scFv) or a peptide (21, 22, 24). The later generation (second and third) of CAR cells integrate an additional domain such as CD28 into the construct, which provides a co-stimulator signal. After the expansion of treated T cells, they are ready for infusion into the patient for 1–2 days. Before CAR T cell infusion, patients receive chemotherapy that reduces lymphoma. Ideally, the target antigen of CAR T cells must be absent on healthy cells but present on cancer cells only (24). To date, for hematological malignancies, several CART therapies have received FDA approval. The first was approved was in August 2017 for the treatment of patients aged up to 25 years carrying B-cell precursor acute lymphoblastic leukemia (ALL) to CD19 cell therapy CART-4-1BB (tsgenlecleucel CTL019, Kymriah, Novartis, Basel, Switzerland) (20, 83, 84). In October 2017, the FDA granted regular approval to CD19 CAR T therapy axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for large B-cell lymphoma adult patients relapsed or
refractory after two extra lines of conventional therapy. They include high-grade B-cell lymphoma, DLBCL NOS, PMBCL, and DLBCL arising from FL (82, 85–87). However, despite the early efficacy observed in the procedure of CAR-T in the treatment of CLL, the initial trials in other NHLs were less promising than the response rates observed in patients with ALL. With improved induction chemotherapy, which has been demonstrated to trigger the patient for rapid expansion of T cells to adoptive transfer, CAR T cells are now showing a more likely response. There have been two reports from an ongoing study of CAR T cells carrying CD19 receptor composed of a recognition ectodomain ScFv and stimulant endodomain 4-1BB (CTL019) that demonstrate the effectiveness both in DLBCL and FCL (82). In the DLBCL cohort as part of an ongoing phase II study, 40 cases were evaluable for assessing the response at the time of data blocking (NCT03761056).

The lymphodepletion regimen before CAR T cell infusion is dependent on the organization of the institution. Moreover, the protocols for the design of CAR T cells growing and producing lentivirus or retrovirus for cell transduction also differ between studies. The timing of infusion of CAR T cells either after chemotherapy alone or immediately after autologous transplantation need to be standardized. Additional multicenter studies are needed to optimize CAR T cell protocols.

Two CAR-T therapies targeting CD19 on B cell malignancies, Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel, were both effective against multiply recurrent DLBCL. In ZUMA-1, axi-cel resulted in a median duration of response, PFS and OS of 11, 6, and >27 months, respectively (88). In JULIET, relapse-free survival with tisagenlecleucel 1 year after initial response was 65 percent (89). Both agents are associated with serious complications (e.g., fatal neurologic events and cytokine release syndrome), but no new toxicities were identified with longer follow-up. Axi-cel and tisagenlecleucel are approved for use at certified institutions by the US FDA in adults with RR DLBCL after ≥2 lines of systemic therapy.

Several studies report some cases that remain resistant to CAR T cells. The resistance can partly be due to the failure of the CAR T cell to overcome the inhibition created by the neoplastic cells. Therefore, studies are ongoing that combine CAR T cell therapy with inhibitors of the mAB control immune system. One trial being conducted at the University of Pennsylvania is exploring pembrolizumab following CAR T cells (NCT02650999). Another trial at Baylor College of Medicine (Houston, TX, USA) combines ipilimumab with CAR T cells (NCT00586391). An alternative mechanism of CAR T cell deficiency is the absence of perseverance of genetically modified CAR T cells. Research is underway to assess whether cytokine co-administration can improve the clonal expansion of CAR T cells (NCT00968760) (24).

CAR T Cells-Toxicities

Cytokine release syndrome (CRS) is possibly one of the leading adverse events of CAR T cell therapy. CRS is related to an elevated number of different cytokines, comprising interleukin-6 (IL-6) and interferon γ. CRS is shown by cumulative adverse events including fever, hypoxia and hypotension. Also, several blood values are altered, such as elevated C-Reactive Protein (CRP), low fibrinogen and highly elevated ferritin. By CAR T cell therapy, the beginning of symptoms correlates with the expansion of T cells, and it is usually evident within days or a few weeks (23). The percentages and severity of CRS therapy in patients with lymphoma are less recurrent than those with high levels of systemic disease such as ALL. The ability of CAR T cells to cross the blood-brain barrier (BBB) and deliver neurological toxicity to the CNS has been documented. A clinical study detected neurological toxicity with CAR T-cell infusion, 3/20 patients presented neurologic toxicity including delirium and 1/20 encephalopathy. The worst of the neurological adverse events are attenuated by the administration of dexamethasone, which also enters the BBB. Due to the exhaustion of non-malignant CD 19 lymphocytes, B cell aplasia is an additional adverse event. Finally, other major adverse events for patients are opportunistic infections due to hypogammaglobulinemia. Hypogammaglobulinemia has efficaciously contrasted with IV immunoglobulin administration after CAR T cell infusion (24, 90–94).

Bispecific Antibodies

Bispecific antibodies (bs-mAbs) are engineered antibodies able to bind two antibodies in a unique molecule and gain the capacity to target diverse epitopes simultaneously. The Bs-mAbs mechanism is analogous to the CAR-T cells, but unlike the latter, the bs-mAbs are “ready to use” drugs (68, 95–98). The identification of the tumor-specific antigen and straight involving T cells can increase the effectiveness of antibody therapy and minimize the toxicity. A BiTE® (Bispecific T-cell engager) antibody complex consists of a single fusion polypeptide (50-60 kDa) able to link two variable fragments of single chain antibodies (scFv) (99). It carries two specific binding sites, one for a link to specific B cell markers (i.e., CD19) and another that targets a co-stimulator on T cells (i.e., CD3) (24). This simultaneously activity results in T cell activation, proliferation, and T cell-induced target cell lysis (100). Differently to the “living” and self-expandable T cells, bsAbs have a short persistence limit in the patient and low objective in strongly immunosuppressed patients. A fusion of both principles can be the modification of immune or tumor cells to permanently express bispecific molecules (101).

AFM13 is a bi-specific, tetravalent chimeric antibody construct (TandAb) designed to recruit natural killer (NK) cells via CD16A as immune effector cells to CD30-expressing malignancies. AFM13 will be tried in a larger phase II trial in HL (NCT02321592) in a study with CD30-positive cutaneous lymphoma (NCT03192202) and in combination with pembrolizumab (NCT02656560) (98, 102).

Blinatumomab (MT103) is the earliest bispecific construct CD19/CD3 approved by the FDA and the EMA for the cure of R/R ALL. Blinatumomab showed high response rates at very low doses in patients with NHL and ALL B precursor. Blinatumomab contains an anti-CD3 arm and an anti-CD19 arm, allowing the junction of CD3 + T cells with the CD19 + B tumor cells. This mechanism determines the lysis of target cells and resembles T-cell-mediated killing (103, 104).
DART proteins (dual affinity retargeting) with a mechanism similar to BiTE® interact with CD3 and CD19. The DART is a new bispecific antibody engineered to overwhelm the mechanical limits of BiTE® to increase stability. DART is composed of diabody-like molecules that have the heavy variable chain ( VH) region linked to the variable light (VL) of the second binder, and the VH of the second variable region linked to the VL of the first (96). Early on, DART was revealed to induce cytotoxicity in in vitro experiments, exhibited potent activity in several relevant tumors and showed more power than the BiTE® format (105). DART was also revealed to be reliably more effective in eradicating CD19-positive B cells. Notably, without engagement with targeted CD19-positive cells, no activation of T-cells by the DART molecule was observed. Also, in vivo in a xenograft mouse model, a DART molecule targeting CD19 assembled using an exclusive anti-T cell receptor antibody portion showed an activity virtually identical to that of the CD19 x CD3 DART molecule (106, 107). The DART setup is mostly attractive for clinical practice since it has been confirmed to have comparable pharmacokinetics with other mAbs. The earliest study on a DART CD19xCD3 was in patients with R/R NHL (96).

Mosunetuzumab is a full-length bispecific CD20/CD3 antibody that redirects endogenous T-cells to kill neoplastic B-cells by concomitantly binding to CD3 on T cells and CD20 on B cells. An ongoing multicenter Phase I/IB study (NCT02500407) is evaluating mosunetuzumab in R/R B cell NHL patients. The interim analysis shows that mosunetuzumab monotherapy is clinically active in this cohort of NHL, thus it is showing promising and durable efficacy in FCL and DLBCL.

**BiTE-Toxicities**

Accepting the risk of neurotoxicity and CRS, blinatumomab and other BiTE would be given gradually and with weekly progressive doses (24, 108). A phase I/II study of blinatumomab reported several adverse events including CRS, neurotoxicity (aphasia, ataxia, convulsions, headache, tremor), and leukopenia/neutropenia. Also, in the blinatumomab phase study, <10% of NHL patients have been grade 3 CRS or higher. Instead, in the phase II study, “early” prophylactic dexamethasone was used for each initiation, and an increased daily blinatumomab infusion dose for 2 days after the start reported no adverse events with CRS (109).

**SMALL MOLECULES INHIBITORS (SMIs)**

Although monoclonal antibodies and other immunotherapies have led to dramatic advances in the treatment of lymphoma patients, the parallel development of small molecule inhibitors has been equally exciting. These SMIs have reformed the therapeutic model for different subtypes of NHL. Many SMIs have been approved by the FDA, and others are still under evaluation. Several SMIs are administered orally, are moderately well-tolerated and offer patients unprecedented response rates. Their small size (≤500 Daltons) allows for interchange through the plasma membrane, enabling the interaction with intracellular signaling molecules and the cytoplasmic domain of cell surface receptors. These SMIs inhibit signal transduction pathways by targeting proteins involved in transcriptional/translational regulation, protein stability, cell cycle regulation of mitosis and apoptosis. These new agents are a heterogeneous group of drugs with different mechanisms of action: (i) B cell receptor signaling Inhibitors like TKI, BKI, Aurora Kinase Inhibitors (AKI), and SYK; (ii) proteasome inhibitors and; (iii) HDAC inhibitors (Table 1). The SMIs are not free from toxicity, especially when combined with other drugs. Therefore, we will provide advice on the relevant toxicity profiles, because these promising new treatments could hide pitfalls for the treatment of patients with NHL. In clinical practice, these new agents generate a multifaceted step in pharmacokinetics (PK), which does not encompass broad individual PK variability and unpredictable outcomes according to the pharmacogenetic profile of the patient (e.g., cytochrome P450 enzyme) (10, 17, 110, 111).

**B Cell Receptor Signaling Inhibitors**

Signaling mediated by B cell receptors (BCR) plays a fundamental role in the expansion of B cell neoplasms. Antigenic stimulation of the BCR extracellular domain starts a signaling cascade accountable for several B cell functions and proliferation. This signal leads to the enrollment of CD79a and CD79b, leading to activation of the spleen tyrosine kinase (SYK) and the LYN kinase. SYK and LYN phosphorylated tyrosine-based immunoreceptor activators activate Bruton tyrosine kinase (BTK) and inositol phosphatidyl three kinase δ (PI3Kδ) (111–115). Inhibitors of BTK, PI3Kδ, and the SYK have been designed to block kinases in this way (17).

**BTK Inhibitors**

Ibrutinib (PCI-32765) is an irreversible oral inhibitor of BTK that binds the active site cysteine-481 (Cys481) of the BTK enzyme. BTK is mainly expressed on—but not limited to—B cells, and ITK is mainly expressed on T cells (111–113). Though chemoimmunotherapy is the standard of care for patients eligible with CLL, its toxicity and risk of infection exclude its use in frail patients (elderly and those with co-morbidities). Another restriction to the treatment group consists of patients carrying 17p aberrations of the TP53 gene as poorly endowed with ordinary chemoimmunotherapy (116, 117). The combination of ibrutinib with mAbs also led to high response rates, with ORRs of 95% with rituximab, 71–100% with oratituumab, and 88% with ublituximab (118, 119). However, there was abrogation of induced lymphocytosis from therapy although it is not yet clear how meaningfully the combination affects the depth and duration of the response (DOR) equated only to ibrutinib (17). Ibrutinib has been tried in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE). It is also used, as well as rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP), in the second line rescue therapy for R/R DLBCL patients. Ibrutinib was evaluated in R/R FCL and R/R MCL in several clinical trials as monotherapy and combinations.

The second generation BTK inhibitors include acalabrutinib (ACP-196) and underdevelopment ONO-4059 (GS-4059), BGB-311, and CC-292. Acalabrutinib is an irreversible BTK inhibitor with a shorter pharmacokinetics t½. It does not inhibit EGFR and other TK receptors. In a phase I study, 95% of patients with...
R/R CLL carrying the 17p alteration accounted for the median at a follow-up of 14 months. A common adverse event was diarrhea and bleeding, but no atrial fibrillation was reported (120). It is improbable that ACP-196 is effective in patients with ibrutinib resistance (120). But its use in intolerance to ibrutinib patients is now under investigation (NCT02717611). Other second-generation BTK inhibitors have accounted for effectiveness (121–123). It remains to be understood whether these molecules will have a noteworthy effect compared to ibrutinib.

**BTK-Toxicities**

The most common adverse effects were non-hematologic toxicities, including muscle spasms, nausea, fatigue, diarrhea, skin rash, and arthralgia. Hematologic toxicities were less common and included several grades of neutopenia, thrombocytopenia, and anemia (124).

**PI3K Inhibitors**

More downstream from BTK is PI3K. Ubiquitous PI3K fits a highly conserved family of kinases with specific tissue isoforms α, β, γ, and δ. The isoform δ is present on leukocytes and is, therefore, a target of interest. The γ isoform has been associated with the growth and signaling of T cells. The inhibition of p110δ has been revealed to reduce the downstream signaling of the BCR, CXC 4 receptor (CXCR4), and 5 (CXCR5) chemokines. In preclinical studies, it resulted in decreased protein kinase B (AKT) activation, a molecular target of rapamycin (mTOR) and other pathways (111). The PI3K inhibitors currently in use and under investigation in lymphomas are Idelalisib, Copanlisib, Buparlisib, and Umbralisib. Overall, PI3K inhibitors seem to have low response rates in patients with R/R DLBCL when used as monotherapy. It should be studied in combination with other new agents with carefulness to minimize latent toxicity (125).

**Buparlisib** is a strong PI3K oral inhibitor that has confirmed effects in *in vitro* and *in vivo* models of hematologic malignancies (126–128).

**Copanlisib** is an intravenous class I directed against isoforms PI3K-γ and PI3Kδ (129). To assess the effectiveness of copanlisib in DLBCL, patients were treated with 60 mg (130). Copanlisib was evaluated in both indolent and aggressive lymphomas (130–133).

**Idelalisib** (CAL-101) is a potent and highly specific inhibitor of the PI3K δ isoform. It is approved for refractory indolent lymphoma (134, 135). Idelalisib has shown activity either as a single agent and/or in combination with mAbs in R/R CLL in FCL and HL (136–142).

**Duvalisib** is an oral inhibitor of PI3K δ and γ isoforms showing activity in the small non-randomized study of patients with multiply relapsed FL. It is approved by the FDA as a single agent for the treatment of relapsed FL patients who received at least two previous conventional therapies. In this study, CRs are quite uncommon although ~40% of patients achieve a PR. More recently, a small single-arm multicenter trial (DYNAMO) of duvelisib in multi-relapsed patients with CLL/SLL, MZL, and FL reported response rates over 40 percent with an estimated median duration of response of 9.5 months. CLL/SLL patients had a better outcome than the other subtypes (143). Fatal and/or serious toxicities could be seen, including opportunistic pneumonitis from *P. jirovecii* pneumonia, diarrhea or colitis, and cutaneous reactions.

**Umbralisib** is the latest oral inhibitor of both PI3Kγ and casein kinase 1ε (CK1ε).

**PI3K Inhibitor Toxicities**

PI3K inhibitors have a distinctive toxicity profile, including severe diarrhea/colitis. Grade 3 or higher toxicity has been reported with an incidence of around 15%. In addition, opportunistic infections including pneumocystis jirovecii pneumonia (PJP) and cytomegalovirus (CMV) have been recognized in patients treated with idelalisib (144–146).

**SYK Inhibitors**

Other components of BCR signaling are potential targets include LYN and SYK as described above (20). SYK is an SH2 domain-containing tyrosine kinase activity. Constitutive activation by SYK leads the development of NHL. It is noted that DLBCL tissue overexpresses the components of the BCR signaling pathway, including SYK. Inhibition of SYK remains a promising goal, but it should be combined with other drugs to produce lasting and meaningful responses (147).

**Cerdulatinib** (PRT062070) is an oral kinase dual inhibitor of JAK 1/3 and SYK and has been revealed in *in vitro* experiments to have a specific inhibitory action in a subgroup of B-cell lymphoma cell lines (148). Cerdulatinib inhibited B-cell activation in a murine model of chronic BCR stimulus. In DLBCL cell lines, cerdulatinib induced apoptosis, blocking cell-cycle, BCR and JAK/STAT signaling (149). It has been described as having synergistic action of cerdulatinib and venetoclax in primary a CLL primary cell line (150). Remarkably, cerdulatinib showed better inhibition of cell duplication than ibrutinib in the ibrutinib-resistant CLL cells and BTKC481S-transfected/ibrutinib-resistant lymphoma cells (147, 151, 152). This double SYK/JAK inhibitor was also evaluated in patients with different R/R B Cell malignancies (153, 154).

**Entospletinib** (GS-9973) is an oral drug that selectively inhibits SYK (155). This 2nd generation molecule showed increased *in vitro* and *in vivo* selectivity for JAK-2, c-KIT, FMS-like tyrosine kinase 3 (FLT 3), VEGFR2, and RET compared to fostamatinib (155). In a multicenter study on subjects with R/R CLL and NHL, entospletinib showed a promising toxicity profile (147). Moreover, in the latest phase II study entospletinib was shown to have low clinical activity in 39 patients with R/R MCL (147, 156).

**Fostamatinib** is an oral Syk inhibitor leading to a reduction in cell survival (157). In this light, good preliminary results were obtained from a double-blind, randomized study enrolling patients with R/R DLBCL who were not suitable for HSCT (158–160).

**TAK659** is a promising selective, reversible SYK and FLT3 inhibitor demonstrated in both *in vitro* and *in vivo* models (161). Inhibition of SYK remains a promising goal, but it should probably be joined with other antineoplastic drugs to harvest lasting and significant responses (111).
SYK Inhibitors Toxicities
The most frequent toxicities observed with SYK Inhibitors are diarrhea, nausea, hypertension and fatigue. Hematological common adverse events are neutropenia and thrombocytopenia (147).

Proteasome Inhibitors (PIs)
The ubiquitin-proteasome pathway is a multifaceted complex responsible for the regulation of proteins involved in neoplastic activity, such as cyclin-dependent kinases (CDK), BCL-2, and NFκB complex (162, 163). The role of the proteasome is upregulation of these key pathways, making it a promising antineoplastic target (10, 164–168). Finding that PIs lead to cell cycle inhibition and apoptosis in tumor cells has pushed them to be developed as antineoplastic agents. The studies revealed a complex system of ubiquitin ligases and related proteins that orchestrate the delicate balance of longevity of proteins within cancer cells. It is thought that the constellation of proteins whose degradation is inhibited by PI interrupts intracellular processes crucial for the survival of tumor cells. Some examples are (1) cell cycle interruption by inhibiting the degradation of CDK such as p21 and p27; (2) inhibition of the nuclear signal transduction pathway of the κB factor (which typically inhibits apoptosis) through the accumulation of the I-κB inhibitory protein; and (3) promoting apoptosis prolonging the function of the pro-apoptotic members of the Bcl-2 proteins, such as Noxa (10, 164–168).

Bortezomib was the first of this class of drugs to undergo clinical development. The first phase 1 study of hematological malignancies showed signs of activity in multiple myeloma (MM), FCL, MCL, and MALT lymphoma (169, 170). It is FDA approved for use in naive and R/R multiple myeloma (MM).

Bortezomib’s success has triggered the evolution of 2nd generation PIs, looking to improve on the activity but to minimize the toxicities (primarily peripheral neuropathy) not only for MM but also as therapeutic alternatives in other diseases, including lymphomas and systemic amyloidosis. The development of carfilzomib has shown noteworthy advancement to being effective and less neurotoxic for patients with relapsed or R/R MM who failed ≥1 preceding line of therapy. Unlike carfilzomib, bortezomib has demonstrated irreversible inhibitory kinetics.

Ixazomib is a second-generation inhibitor of the 20S proteasome that is supplied in both IV and oral drug formulations. Ixazomib has shown efficacy in preclinical lymphoma models (171, 172). This PI has a modest single-agent activity, although so far combination with other drugs has not been shown to increase overall results (111, 173).

Proteasome Inhibitors Toxicities
Proteasome Inhibitors showed a significant toxicity profile: serious neurotoxic side effects, cardiovascular and gastrointestinal toxicities, peripheral neuropathy and cytopenias (174–176). Other symptoms include herpetic zoster reactivation lymphopenia, thrombocytopenia, and persistent fatigue. In addition, although rare a minor proportion of subjects showing cardiac failure was recorded with the 1st generation of PIs (177).

Mammalian Target of Rapamycin-mTOR Inhibitors (mTOR)
mTOR is a keyway in the regulation of trans-membrane trafficking, protein degradation, ribosome biogenesis, protein kinase C signaling, and DNA transcription (178, 179). Thus, triggering of the PI3K/AKT pathway and mTOR signaling is essential in lymphomagenesis. Inhibition of this pathway revealed the blocking of cell duplication (180–182).

Everolimus is an oral mTOR inhibitor (183). The primary studies examined this agent in R/R DLBCL, and afterward for R/R CLL/SLL and R/R HL (184–190).

Temsirolimus is an FDA-approved IV mTOR inhibitor in metastatic renal cell carcinoma (191). The EMA in Europe approved Temsirolimus for MCL, too (192), and temsirolimus was also added to the list of rescue regimens for R/R NHL patients (193, 194).

mTOR Inhibitor Toxicities
mTOR inhibitors are attractive agents since they are well-tolerated as single agents and in combination with other drugs. They have also demonstrated synergism with PIs, leading to the study of combination therapy (10). The side effects include a variety of metabolic, hematological, respiratory, renal, and dermatological toxicities. The tolerability scale of mTORIs, even at the same dosage and for the same application, ranges from excellent to debilitating (e.g., buccal aphthous), can sometimes be fatal (pneumonitis) and may occur at different time points (from days to years) after the initiation of rapalog therapy. Surprisingly, the rate of some side effects, such as pneumonitis or mucocutaneous effects, seems to increase with the dosage of the drug, whereas mTOR is inhibited at the nanomolar range by rapalogs. Alternatively, the majority of these side effects are idiosyncratic and unpredictable (195–197).

BCL2 Inhibitor
Several neoplasms seem to be mainly dependent on a specific balance of Bcl-2 family expression for their survival, and Bcl-2 overexpression can lead to both de novo and acquired chemoresistance (10). The overexpression of the anti-apoptotic BCL-2 protein is frequent in several NHL subtypes, including 30% of the DLBCL (198–201). Inhibition of BCL-2 has become an important treatment strategy because of increasing apoptosis. BCL2 inhibitors were applied primarily for the treatment of CLL patients (111, 202, 203).

Venetoclax is an oral formulation. In preclinical study, it has been shown to have powerful selective “BH3-mimetic” activity independent of BCR signaling (apoptosis free of p53) (204–207). In xenotransplantation models, venetoclax has shown greater efficacy when combined with chemoimmunotherapy. Despite the recurrent overexpression of BCL2, monoclonal venetoclax did not have an equally robust response as expected in the DLBCL, while it seems to be well-tolerated (206, 208). Forthcoming studies focus on multiple combinations of venetoclax to increase responses. The European Commission of Medicines (EMA) has approved the combination of venetoclax plus rituximab (V + R) for the treatment of R/R CLL patients previously treated by other therapies (209–211). EMA approval
is established on the published results of the Phase 3 MURANO randomized trial (210, 212, 213). This trial compared the BCL2 inhibitor venetoclax administered up to a maximum of 2 years, associated in the first 6 months of R treatment, with the classic chemo-immunotherapy regimen bendamustine and rituximab (BR) administered for six cycles every 4 months (210, 213).

**BCL2 Inhibitor Toxicities**

Nausea, diarrhea, anemia, lymphopenia, neutropenia, and thrombocytopenia are the most frequent AEs, with a minor—although enough to grab attention—incidence of tumor-lysis syndrome (214–216).

**HDAC Inhibitors (HDIs)**

Histone deacetylases (HDAC) are enzymes designed against both the histone and non-histone proteins. To date, 18 HDAC enzymes were identified based on their homology with yeast deacetylases. Human HDACs were categorized into four classes: class I includes HDAC 1, 2, 3, and 8, which are located in the nucleus. Class II comprises HDAC 4, 5, 6, 7, 9, and 10, which have a mutable cellular location; class III contains the NAD-dependent yeast homologs, SIRT 1-7, which are not targeted by the currently available HDAC inhibitors (HDACI). Finally, class IV includes HDAC 11 (217, 218). HDIs have been shown to activate cell cycle checkpoints, promote apoptosis, induce cell differentiation, suppress angiogenesis, and improve immune surveillance. HDAC inhibitors (HDI) include a class of synthetic or natural chemical compounds that inhibit the enzymatic activity of HDAC. Several HDIs have been studied in lymphomas, demonstrating only modest clinical benefit, and other HDIs are currently studied in preclinical studies (218, 219).

*CUEDC-907* is a class I-II oral double-inhibitor of HDAC and PI3K (α, β, γ) enzymes (111, 220, 220–222).

*Mocetinostat* is an oral HDI that inhibits class I and IV, specifically HDAC isoforms 1, 2, 3, and 11 (223, 224). Mocetinostat was evaluated in a phase II study in R/R DLBCL patients (18, 111, 223–225).

*Panobinostat* is a potent pan-HDAC inhibitor with low dosage achievement against class I, II, and IV HDAC and is FDA approved for DLBCL (225).

*Vorinostat* is one of the first HDAC inhibitors with activity against HDAC class I and II. It has synergistic antineoplastic action when combined with topoisomerase II inhibitors (111, 226–228).

**HDAC-toxicities**

Even though the HDAC family contains several chemical compounds with selectivity for different HDAC isoforms, they unexpectedly have analogous toxicity profiles. Generally, common non-hematologic AEs are diarrhea, nausea, vomiting, fatigue, anorexia, weight loss, and asthenia. Most common hematologic AEs are thrombocytopenia, anemia, and neutropenia (229).

**NOVEL AGENTS IN MATURE B-CELL LYMPHOMA SUBTYPES WITH INDOLENT BEHAVIOR**

Patients suffering mature B-cell lymphoma with histological subtypes associated with an indolent behavior such as CLL/SLL, FL, MZL, LPL, and a fraction of those with MCL are generally highly responsive to chemotherapy regimens conventionally based on purine analogs, alkylators with or without the inclusion of anthracyclines. However, they remain still incurable and suffer subsequent relapses and a high risk of histological transformation toward a “large cell” histology. Targeted agents have redefined treatment paradigms in this setting of recurrent patients (Table 2). Most patients with FL experience serial relapse and will be treated with many available agents at some point during their disease course. A preferred order for their use has not been established. Novel agents such as idelalisib, copanlisib, or duvelisib and radioimmunotherapy may be used for multiply relapsed indolent B cell lymphomas. The efficacy and safety of novel agents may quietly differ among different subtypes. As an example, Ibrutinib, which achieves high response rates in MCL, accounts for only 21 and 38 percent ORRs in patients with R/R FL, respectively. Results in the setting of recurrent patients have prompted some of these agents, targeting either cell surface antigens, intracellular pathways or the microenvironment, as a possible front-line option (Table 4).

**NOVEL AGENTS IN MATURE B-CELL LYMPHOMA SUBTYPES WITH AGGRESSIVE AND VERY AGGRESSIVE BEHAVIOR**

Due to the high failure rate produced by excessive toxicity and low response rates to conventional chemotherapies (or both), subtypes with aggressive behavior such as DLBCL, the majority of MCL, transformed FCL and Burkitt lymphoma still represent a burning problem and an unmet need in the setting of recurrent patients (Table 3). The myriad of novel agents under development, targeting the new pathways fundamental to aggressive B cell growth is expected to offer added clinical benefit to patients with aggressive B cell NHL. Furthermore, these novel agents characterize sustained advancement in the planning for individualized therapies, as single modality treatment, or combined with chemotherapy or other targeted agents (Table 3).

The anti-PD-1 and anti-PD-L1 treatment approaches, coupled with other agents have produced somewhat disappointing results for recurrent DLBCL (74). Currently, inhibition of PD-1/PD-L1 is used in the clinical trial in combination CAR T cell therapy (NCT02926833 and NCT02706405) or recurrence after CAR-T cell therapy (NCT02650999).

CAR T therapies that target CD19 on B cell malignancies were effective against multiply relapsed DLBCL in initial trials and have confirmed their effectiveness at longer-term follow-up.
### TABLE 2 | Overview of the efficacy of select novel therapies in Mature B-Cell neoplasms: indolent histology.

| Authors               | Drug       | Target | Phase | Setting                                      | N° of pts | ORR% (CR %) | PFS% (y) | PFS median (mo.s) | *AEs                  |
|-----------------------|------------|--------|-------|----------------------------------------------|-----------|-------------|-----------|-------------------|-----------------------|
| Byrd et al. (121)     | Acalabrutinib | BTK    | I     | R/R with 17p alteration                      | 61        | 95%         | NR        | 14.3              | Dyarhea               |
| Byrd et al. (121)     | Ublintuximab | CD20   | II    | Naive. Two arms of 1 g/day and 2 g/day       | 80        | 67%         | NR        | 20.3              | 12% neutropenia in 2 g/day arm |
| Nastoupil et al. (230)| Ublintuximab | CD20   | I     | Dose escalation. Post-Rituximab. In combination with umbralisib, and ibrutinib. | 46        | 84%         | NR        | NR                | 24%                  |
| Ding et al. (83)      | Pembrolizumab | PD-1   | II    | R/R carrying 17p alteration and IGHV unmutated | 16        | 44%         | NR        | NR                |                       |
| Gopal et al. (139)    | Idelalisib  | PI3K   | II    | R/R. In combination to Brivatinib           | 125       | 57% (6%)    | 12% (2 y) | 11                | ND                   |
| Liu et al. (147)      | Entospletinib | Syk    | II    | R/R. dosing 1.6 g/daily                     | 41        | 61%         | NR        | 13.8              | ND                   |
| Seymour et al. (210)  | Venetoclax  | BCL2   | II    | R/R. 17p deletion In combination to Rituximab | 49        | 86%         | 82% (2 y) | NR                | 67%                  |
| Jaglowski et al. (119)| Ibrutinib  | BTK    | 1b/II | R/R with 17p deletion. Dosing 420mg/day. In combination to Ofatumumab | 71        | 83%         | 83% (1 y) | NR                | 11% led discontinuation |
| Rosenthal et al. (18) | Ibrutinib  | BTK    | III   | R/R. In combination to Bendamustine and Rituximab | ND        | 93% (40%)   | 96% (1 y) | NR                | ND                   |
| Younes et al. (231)   | Nivolubam   | PD1    | I     | R/R in combination to ibrutinib             | 40        | 36%         | NR        | 5                 | 13% anemia            |
| Ganjo et al. (232)    | Ocartuzumab | CD20 FcyRilla | I/II | R/R with low affinity genotype FcyRilla | 50        | 30%         | NR        | 9.2               | ND                   |
| Czuczuman et al. (233)| Ofatumumab | CD20   | I/II  | R/R. Dosing 500 mg/day                      | 27        | 22%         | NR        | 5.8               | Neutropenia           |
| Westin et al. (234)   | Pidilizumab | PD1    | II    | R/R. Dosing 3 mg/kg IV every 4 weeks. In combination to Rituximab | 32        | 52%         | NR        | 15.4              | No AEs grade >2       |
| Westin et al. (234)   | Pidilizumab | PD-1   | II    | R/R combined with Rituximab                 | 29        | 66%         | NR        | 18.8              | No AEs grade >2       |
| Gopal et al. (141)    | Idelalisib  | PI3Kd  | II    | R/R. Dosing 150mg twice daily              | 125       | 57% (50%)   | NR        | 11                | Neutropenia 27%       |
| Bartlett et al. (235) | Ibrutinib  | BTK    | I     | Naive in combination with Rituximab. Dosing 560mg/day | 31        | 37.5%       | 80.4% (2y) | 14                | Neutropenia 10%       |
| Davids et al. (236)   | Venetoclax  | BCL2   | I     | R/R to Bendamustine Rituximab. Dosing 1.2 g/day | 29        | 38%         | NR        | 11                | Neutropenia 11%       |
| Noy et al. (237)      | Ibrutinib  | BTK    | II    | R/R. dosage 560 mg/day                     | 63        | 48%         | NR        | 14.2              | pneumonia 8%          |
| Goebler et al. (109)  | Blinatumumab | CD3/CD19 | I    | R/R maximum dose tolerated                 | 25        | 69%         | NR        | 13.5              | ND                   |
| Ansell et al. (238)   | Ipilimumab  | CTLa-4 | I     | R/R. 3 mg/kg/mo.s × 4mo.s                  | 18        | 11%         | NR        | 16                | ND                   |
| Cheson et al. (45)    | Obintuzumab | CD20   | III   | Randomly comparing to bendamustine in R/R to rituximab | 396       | NR          | NR        | 22.5              | ND                   |

*Grade >3 non hematological AEs, only.

ASCT: Autologous Stem Cell Transplantation; B-NHL, B-NHL not otherwise specified; CLL/SLL, Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia; DLBCL, Diffuse Large B cell Lymphoma; FL, Follicular Lymphoma; HG-BCL, High Grade B-cell lymphoma; IGHV, Immunoglobulin G Heavy Variable chain; iNHL, indolent NHL; IV, intravenous; LBCL Large B-cell lymphoma; MCL, Mantle Cell Lymphoma; mo.s, months; MZL, Marginal Zone Lymphoma; ND, Not Documented NR, Not Reached; pts, patients; R/R, Refractory/relapsed; y, years.
TABLE 3 | Novel agents currently under investigation in Mature B-Cell neoplasms: aggressive and very aggressive histology.

| Subtype | Author | Drug | Class/target | Phase | Setting | N° of pts | ORR% | PFS % (y) | PFS (mo.s) | *AEs |
|---------|--------|------|--------------|-------|---------|-----------|-------|-----------|------------|------|
| DLBCL   | Ansell et al. (63) | Nivolumab | Anti-PD1 | II | R/R Failed to ASCT (87 pts), Ineligible to ASCT (34 pts) | 121 | 10% failed 3% ineligible | NR | Failed 12.2 Ineligible 5.8 | 24% |
| DLBCL   | Armand et al. (239) | Pidiluzumab | Anti-PD1 | II | R/R ASCT | 66 | 51% | NR | 16 | ND |
| DLBCL   | Locke et al. (88) | axicabtagene ciloleucel | CD19 | I/II | R/R. 1.0 × 10^6 CAR T cells/Kg | 101 | 83% (58%) | NR | 5.9 | 11% |
| DLBCL   | Shuster et al. (89) | tisagenlecleucel | CD19 | II | R/R. 1.0 × 10^7-6.0 × 10^8 CAR T cells | 93 | 52% 40% | 35% (1 y) | NR | ND |
| DLBCL   | Viardot et al. (110) | Blinatumumab | CD3-CD19 | II | escalation dose 9-28-112 ug/day | 17 | 43% | NR | NR | ND |
| DLBCL   | Wang et al. (240) | Ibrutinib | BTK | II | R/R | 54 | 28% | NR | 3 | ND |
| DLBCL   | Younes et al. (241) | Buparlisib | PIK3 | II | R/R | 26 | 11.5% | NR | 1.5 | 11% |
| DLBCL   | Flinn et al. (158) | Fostamatinib | Syk | I/II | Ineligible for ASCT, Dosing 200 mg/day | 47 | 21% (4%) | NR | 5.3 | ND |
| DLBCL   | Rhodes et al. (112) | TAK659 | Syk/FLT3 | II | R/R | 77 | 27% | NR | NR | ND |
| B-NHL   | Witzens-Harg et al. (194) | Temsirolimus | mTOR | II | In combination with rituximab, Dosing 24, 50, 75, or 100 mg | 32 | 28% (12.5%) | NR | 2.6 | ND |
| DLBCL   | Rhodes et al. (112) | Vorinostat | HDAC | I/II | In combination to R-CVEP | 16 | 57% | NR | 9.2 | ND |
| DLBCL   | Batlevi et al. (225) | Moctostat | HDAC | II | R/R | 72 | 18.9% | NR | 2.1 | ND |
| DLBCL   | Oki et al. (242) | CUJDC-907 | HDAC/PIK3 | II | R/R (14 of them with Myc altered), with or without Rituximab | 37 | 37% 64% in Myc altered | NR | 11.2 13.6 in Myc altered | Neutropenia |
| HG-BCL  | Dryling et al. (131) | Copanlisib | PI3K-γ and PI3K | II | CD79b mutations | 43 | 25% | NR | 2 m | ND |
| MCL     | Wang et al. (243) | Lenalidomide | PIs | II | R/R to Ibrutinib | 58 | 29% | NR | 5 | No AEs grade >2 |
| MCL     | Younes et al. (241) | Buparlisib | PIK3 | II | R/R | 22 | 22.7% | NR | 11.3 | ND |
| MCL     | Jerkeman et al. (244) | Ibrutinib | BTK | II | R/R in combination to Rituximab and Lenalidomide | 50 | 76% | NR | 17.8 | Neutropenia 38%, Infection 22% |

*Grade >3 non-hematological AEs, only.
ASCT, Autologous Stem Cell Transplantation; B-NHL, B-NHL not otherwise specified; CLL/SLL, Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia; DLBCL, Diffuse Large B cell Lymphoma; FL, Follicular Lymphoma; HG-BCL, High Grade B-cell lymphoma; IGHV, Immunoglobulin G Heavy Variable chain; iNHL, indolent NHL; IV, intravenous; LBCL Large B-cell lymphoma; MCL, Mantle Cell Lymphoma; mo.s, months; MZL, Marginal Zone Lymphoma.; ND, Not Documented NR, Not Reached; pts, patients; R-CVEP, rituximab, cyclophosphamide, vorinostat, etoposide, and prednisone; R/R, Refractory/relapsed; y, years.
| Drug | Target | Histologic subtype | Study phase | Schedule | Setting (planned enrollment) | Current trials |
|------|--------|--------------------|-------------|----------|----------------------------|----------------|
| **ANTI-CD mAbs** | | | | | | |
| Camidanlumab Tesirine | CD25 | B-NHL | I | Single Agent, Adaptive Dose-Escalation Study | R/R (140 pts). R/R (70 pts). Random Veltuzumab vs Epratuzumab | NCT02432235 NCT01101581 |
| Epratuzumab | CD22 | HG-BCL | I/II | Randomized: 90Y-Epratuzumab wk 2 3 (days 8 & 15) | R/R (25 pts) | NCT02393157 |
| Obinutuzumab | CD20 | B-NHL | II | Randomized: Single Agent vs. O-ICE | R/R (60 pts) in combination to rituximab. In addition to bendamustine | NCT02361346 |
| Ofatumumab | CD20 | CLL/SLL | I | Dose finding | R/R (314 pts) in combination to rituximab. In addition to bendamustine | NCT02257567 |
| Polatuzumab Vedotin | CD79b | DLBCL FL | Ib/II | Randomized: Pola+Rituximab vs. pola+Rituximab+Bendamustine | R/R CD20 Directed Antibody Therapy | NCT01647971 |
| Ublituximab | CD20 | B-NHL | I/II | 450 mg followed by 600 mg, 900 or 1,200 mg in each cohort | R/R CD20 Directed Antibody Therapy | NCT01647971 |
| **IMMUNE CHECKPOINT INHIBITORS** | | | | | | |
| Atezolizumab | PD-L1 | DLCBL | II | 18 cycles followed by 12 mos of observation | R/R (114 pts) IPI-score ≥ 3 in patients to R/R R-CHOP | NCT03463057 |
| Durvalumab | PD-L1 | CLL/SLL | I/II | 1,500 mg (IV) infusion on Day 1 of Cycles 1 through 13 | R/R (106 pts) in combination to Bendamustine, Lenalidomide and Rituximab in 4 arms | NCT02733042 |
| Ipilimumab | CTLA-4 | DLBCL | I/II | Ipilimumab mg/kg nivolumab 3 mg/kg | R/R (13 pts) whom are ineligible for ASCT. | NCT03505445 |
| Nivolumab | PD-1 | FL | I | 240 mg IV q2-weekly for four cycle | Naive (39 pts). | NCT03245021 |
| Pembrolizumab | PD-1 | DLBCL | I/II | 200 mg IV infusion (day 1), oral CXD101 20mg twice daily. | R/R (45 pts). In combination to CXD101 HDAC inhibitor | NCT03873025 |
| Pidilizumab | PD-1 | NHL | I/II | Dose safety | R/R (109 pts). In combination with ibrutinib. Three arms | NCT02401048 |
| **(CAR) T-CELL THERAPY** | | | | | | |
| Isocabtagene maraleucel | CAR-T | HG-BCL | II | Single dose intravenous | R/R (50 pts). | NCT03744467 |
| Axicabtagene ciloleucel | CAR T-4-1BB | DLBCL | II | Single infusion of CAR-T post Flu darabina and cyclophosphamide. | High risk (40 pts). | NCT03761056 |
| Axicabtagene ciloleucel | CAR T-4-1BB | DLBCL | II | single infusion of CAR-T | R/R (350 pts). Randomized vs. standard protocols (i.e., R-ICE) | NCT03391466 |
| **BISPECIFIC ANTIBODIES** | | | | | | |
| Blinatumomab | CD19/CD3 | NHL | II | Dose escalation 9–28 μg/dy | R/R (28 pts). Single agent | NCT02811679 |
| Mosunetuzumab (BTCT4465A) | CD20/CD3 | NHL and CLL/SLL | I/ib | atezolizumab 1200 mg IV infusion in combination with Mosunetuzumab. | R/R (665 pts) in combination to Atezolizumab | NCT02000407 |

ASCT, Autologous Stem Cell Transplantation; B-NHL, B-NHL not otherwise specified; CLL/SLL, Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia; DLBCL, Diffuse Large B cell Lymphoma; FL, Follicular Lymphoma; HG-BCL, High Grade B-cell lymphoma; IGHV, Immunoglobulin G Heavy Variable chain; iNHL, indolent NHL; IV, intravenous; LBCL, Large B-cell lymphoma; MCL, Mantle Cell Lymphoma; mo.s, months; MZL, Marginal Zone Lymphoma; ND, Not Documented NR, Not Reached; pts, patients; R-ICE, rituximab, cyclophosphamide, etoposide; R/R, Refractory/relapsed; y, years.
### TABLE 5 | Ongoing trials of signal transduction pathway inhibitors in mature B cell neoplasms.

| Drug                          | Target         | Histologic subtype | Study phase | Schedule                      | Setting (planned enrollment)                                                                 | Current trials |
|-------------------------------|----------------|--------------------|-------------|-------------------------------|-----------------------------------------------------------------------------------------------|----------------|
| **BCR INHIBITORS**            |                |                    |             |                               |                                                                                              |                |
| Acalabrutinib                 | BTK            | HG-BCL             | I           | IV infusion days 1, 3, 5      | R/R (42 pts)                                                                                   | NCT03527147   |
| Ibrutinib                     | BTK            | MCL                | III         | 1 tablet/day                  | Randomized in combination to Venetoclax (287 pts)                                             | NCT03112174   |
| Ibrutinib                     | BTK            | DLBCL              | Ib Dose Finding | 1 tablet/day until disease progression | R/R (30 pts) in combination to Rituximab and Venetoclax                                        | NCT03136497   |
| LOXO-305                      | BTK C481 mutation | CLL/SLL           | I/II        | 25 mg/day                     | R/R with C481 mutation in BTK gene.                                                            | NCT03740529   |
| Copanlisib                    | PI3K           | B-NHLnos           | Ib/II       | Days 1, 8, and 15 of a 28-day cycle | R/R (25 pts)                                                                                   | NCT02342665   |
| Duvelisib                     | PI3KI + γ      | CLL/SLL            | I/II        | Orally twice daily            | R/R (47 pts) in combination with Venetoclax                                                   | NCT03534323   |
|idelalisib                     | PI3K I         | CLL/SLL INHL       | II          | 1 tablet/day (cycle 21 days)  | R/R (68 pts). Combination to Pembrolizumab                                                     | NCT02332980   |
| Cer dulatinib (PRT062070)     | SYKJAK 1-2     | FL, DLBCL          | I/IIa       | Dose finding                  | R/R (283 pts)                                                                                   | NCT01994382   |
| TAK659                        | SYK/FLT3       | FL, MZL            | I           | 60-80 mg/day                  | R/R (47 pts). Single agent                                                                       | NCT03238651   |
| **PROTEASOME INHIBITORS**     |                |                    |             |                               |                                                                                              |                |
| Bortezomib                    | Pts            | B-NHLnos           | I/II        | MTD                           | R/R (56 pts). Combination to Gemcitabine and Rituximab                                         | NCT00633369   |
|Ixazomib                      | 20S subunit    | INHL               | II          | once weekly × 4 wk            | R/R (30 pts). In combination to Etoposide and Cyclophosphamide                                 | NCT01614197   |
| **mTor- INHIBITORS**          |                |                    |             |                               |                                                                                              |                |
|Temsrolimus                    | mTor           | Lymphoblastic Lymphoma | I      | Day 1-8 IV                    | R/R (30 pts). In combination to Etoposide and Cyclophosphamide                                 | NCT01614197   |
| **BCL2 INHIBITOR**            |                |                    |             |                               |                                                                                              |                |
|Venetoclax                     | BH3 domain     | DLBCL              | Ib          | 1 tablet/day (cycle 28 day)   | R/R (30 pts). In combination with Rituximab with 17p deletion                                 | NCT03136497   |
| **HDAC INHIBITORS**           |                |                    |             |                               |                                                                                              |                |
| CUDEC-907                     | Class I and II-PI3K | DLBCL            | II          | ND                            | R/R (200 pts) with Myc alteration                                                              | NCT02674750   |
|Mocetinostat (MGCD0103)        | Class I and IV | DLBCL              | II          | 70 mg/3 times per week on a 28 day | R/R (7 pts) with mutations of Acetyltransferase Genes                                          | NCT02282358   |
|Panobinostat                   | Class I, II and IV | DLBCL            | II          | 30 mg/day                     | R/R (42 pts). Randomized with or without Rituximab                                             | NCT01238692   |
|Tazemetostat                   | EZH2           | DLBCL FL           | I/II        | Dose escalation               | Single agent (420 pts)                                                                          | NCT01897571   |
| Vorinostat                    | Class I and II | DLBCL, FL         | I           | Days 1-5 and 8-12. Cycle 21 days | R/R (60 pts). In combination to Pembrolizumab                                                   | NCT03150329   |

ASCT, Autologous Stem Cell Transplantation; B-NHL, B-NHL not otherwise specified; CLL/SLL, Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia; DLBCL, Diffuse Large B cell Lymphoma; FL, Follicular Lymphoma; HG-BCL, High Grade B-cell lymphoma; IGHv, Immunoglobulin G Heavy Variable chain; iNHL, indolent NHL; IV, intravenous; LBCL, Large B-cell lymphoma; MCL, Mantle Cell Lymphoma; mo.s, months; MZL, Marginal Zone Lymphoma; ND, Not Documented NR, Not Reached; pts, patients; R-CHEP, rituximab, cyclophosphamide, etoposide, and prednisone; R/R, Refractory/relapsed; y, years; MTD, maximum tolerated dose; wk, week; sd, standard dosage.
CONCLUSION AND FUTURE OUTLOOK

The development of drugs in lymphomas has undergone substantial changes in the last decade. An endeavor is ongoing to change conventional chemotherapy, with more targeted molecules directed against cell complexes and pathways that are explicitly related to lymphomagenesis. An overview of the ongoing trials is finally provided (Table 4). While mAbs have been the first trend of targeted therapies, there is now a new generation of biological agents, and more of them with an oral formulation, that takes full advantage of a superior understanding of lymphomagenesis. In addition, they have achieved outstanding results especially in subtypes with indolent behavior. Immune therapy with Cls and other models such as CAR-T cells and bispecific antibodies have shown promising results in mature B-cell lymphomas with aggressive behavior where other targeted agents have unfortunately demonstrated only modest improvements. Combined targeted therapy and chemotherapy will be a promising therapeutic strategy and is currently being exploited in ongoing trials (Tables 4, 5).

However, early identification and appropriate management of toxicities should represent a significant issue since important adverse events have been reported, due to both on- and off-target effects, which have already been demonstrated to be unpredictable, leading to the early closure of some studies. Most notably, the occurrence of unforeseen immune events has highlighted the pitfalls of novel drugs emblematically, either as a single agent and/or in combination. Immune/inflammatory toxicities have been reported with checkpoint immunotherapy and combinations of PI3K/SYK inhibitors while hematologic toxicities are pronounced with the BCL-2 inhibitors and standard chemotherapy (245).

With the current knowledge of target therapies, each patient’s cancer biology may be driven to the best cancer treatment.

AUTHOR CONTRIBUTIONS

SC and RaD wrote the manuscript. SC, MB, and PR selected bibliography. SC and GR prepared Figure 1. PV and SM prepared the Table 1. RoD and AP over-reviewed the manuscript.

REFERENCES

1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. (2016) 127:2375–90. doi: 10.1182/blood-2016-01-643569
2. Rizvi MA, Evans AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood. (2006) 107:1255–64. doi: 10.1182/blood-2005-03-1306
3. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: B-cell non-Hodgkin lymphomas. Expert Rev Hematol. (2017) 10:405–15. doi: 10.1080/17474086.2017.1318053
4. Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. (2018) 182:633–43. doi: 10.1111/bjh.15412
5. El-Mallawany NK, Cairo MS. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol. (2015) 13:113–23.
6. Mei M, Chen R. How to approach a Hodgkin lymphoma patient with relapse after autologous SCT: allogeneic SCT. Clin Lymphoma Myeloma Leuk. (2018) 18:26–33. doi: 10.1016/j.clml.2017.11.003
7. Shantbag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. (2018) 68:116–32. doi: 10.3322/caac.21438
8. Biccler JL, El-Galaly TC, Bogsted M, Jorgensen J, de Nully Brown P, Poulsen CB, et al. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas. Leuk Lymphoma. (2018). doi: 10.1080/10428194.2018.1540044. [Epub ahead of print].
9. Barth MJ, Minard-Colin V. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. (2019). doi: 10.1111/bjh.15783. [Epub ahead of print].
10. Al Juhaisi T, Yazbeck V. Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: does one size fit all? Expert Opin Pharmacother. (2019) 20:773–5. doi: 10.1080/14656566.2019.1582643
11. Gerecitano J. The future of small molecule inhibitors in chronic lymphocytic leukemia. Ann Oncol. (2018) 29:525. doi: 10.1093/annonc/mdx061
12. Lange J, Lenz G, Burkhardt B. Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications. Expert Rev Hematol. (2017) 10:123–35. doi: 10.1080/17474086.2017.12 71318
13. Wang TP, Scott JH, Barta SK. The evolving role of targeted biological agents in the management of indolent B-cell lymphomas. Ther Adv Hematol. (2017) 8:329–44. doi: 10.1177/2046366717753740
14. Merryman RW, Armand P, Wright KT, Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. (2017) 1:2643– 54. doi: 10.21203/s6.aol.2017.08.03
15. Horn H, Staiger AM, Ott G. New targeted therapies for malignant lymphoma based on molecular heterogeneity. Expert Rev Hematol. (2017) 10:39– 51. doi: 10.1080/17474086.2017.1268046
16. Rosenthal A. Small molecule inhibitors in chronic lymphocytic leukemia and B cell non-Hodgkin lymphoma. Curr Hematol Malig Rep. (2017) 12:207– 16. doi: 10.1007/s11899-017-0583-0
17. von Keudell G, Younes A. Novel therapeutic agents for relapsed classical Hodgkin lymphoma. Br J Haematol. (2019) 184:105–12. doi: 10.1111/bjh.15695
18. Marron TU, Kalac M, Brody J. An update on the use of immunotherapy in the treatment of lymphoma. Curr Hematol Malig Rep. (2017) 2:128– 9. doi: 10.1007/s11899-017-0396-8
19. Wang M, Liu Y, Cheng Y, Wei Y, Wei X. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochim Biophys Acta Rev Cancer. (2018) 1871:199–224. doi: 10.1016/j.bbcan.2018.12.002
20. Rossig C. Cancer immuno-oncology: novel Therapeutic approaches. Expert Rev Immunol. (2018) 18:54–8. doi: 10.1016/j.clim.2017.09.016
21. Copelan EA. CAR T-cell therapy in non-Hodgkin lymphoma patients. Oncology. (2019) 33:73–4.
22. Nair R, Neelapu SS. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol. (2018) 31:293–8. doi: 10.1016/j.beha.2018.07.011
23. Pishko A, Nasta SD. The role of novel immunotherapies in non-Hodgkin lymphoma. Transl Cancer Res. (2017) 6:93–103. doi: 10.21037/tcr.2017.01.08
24. Marrocco I, Romaniello D, Yarden Y. Cancer immunotherapy: the dawn of antibody cocktails. Methods Mol Biol. (2019) 1904:11–51. doi: 10.1007/978-1-4939-8958-4_2
31. Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Bottcher S, Bahlo J, et al. Brentuximab vedotin in classical Hodgkin lymphoma and may be excellent targets for immunotherapy expressing hematological malignancies. Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity and demonstrates modest biologic evidence of CD40 mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activated. Blood (2007) 104:2463-4491.

38. Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, et al. Polatuzumab vedotin combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL): preliminary results of a Phase Ib dose-escalation study. Blood (2016) 128:1856.

39. Flynn MJ, van Berkel P, Zammarchi F, Levy JN, Tiberghien A, Masterson LA, et al. Pre-clinical activity of Adct-301, a novel pyrrolobenzodiazepine (PBD) dimer-containing Antibody Drug Conjugate (ADC) targeting CD25 expressing hematological malignancies. Mol Cancer Ther. (2016) 15:2709–21. doi: 10.1158/1535-7163.MCT-16-0233.

40. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol. (2009) 27:4371–7. doi: 10.1200/JCO.2008.21.3017

41. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol. (2009) 27:4371–7. doi: 10.1200/JCO.2008.21.3017

42. Burington B, Advani R, Shi XY, Yue P, Lau J, Yu SF, et al. A gene signature approach to primary effusion lymphoma. J Natl Cancer Inst. (2018) 110:460–74. doi: 10.1093/jnci/djy122.

43. Cheon BD, Treneny M, Boudaballah K, Dueck G, Gribben J, Lugtenburg PJ, et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN Study. Blood. (2016) 128:615.

44. Teeling JL, Mackus WJM, Wiegman LJMJ, Van den Brakel JHN, Reers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. (2006) 177:362–71. doi: 10.4049/jimmunol.177.1.362

45. Maloney DG, Fukuhara N, Ogura M, Larouche JF, Tournilhac O, Coleman M, et al. Phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab containing therapy (homer): results of the interim analysis. Haematologica. (2016) 101:102.

46. Palanca-Wessels MC, Finn IW, Sehn LH, Patel M, Sangha R, Cruzman MS, et al. A Phase I study of the anti-CD279 Antibody-Drug Conjugate (ADC) DCDS4501 A targeting CD279 in relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Blood. (2012) 120:36.

47. Sehn LH, Herrera AF, Matasar MJ, Kamarad M, Assouline S, Hertzberg M, et al. Polatuzumab vedotin (pola) plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): preliminary results of a Phase IIb/Bll study. Blood. (2018) 121:1683. doi: 10.1182/blood-2018-99-118551

48. Maloney DG, Fukuhara N, Ogura M, Larouche JF, Tournilhac O, Coleman M, et al. Phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab containing therapy (homer): results of the interim analysis. Haematologica. (2016) 101:102.

49. Marshall ME, Stopforth R, Crisp SJ. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. (2017) 8:425. doi: 10.3389/fimmu.2017.00425

50. Salles G, Barrett M, Foa R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. (2017) 34:2232–73. doi: 10.1007/s12261-016-1535-8.

51. Kolibaba K, Burke JM, Brooks HD, Maehadevan D, Melear J, Farber CM, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with untreated Diffuse Large B-Cell Lymphoma (DLBCL): preliminary results of a Phase Ib dose-escalation study. Blood. (2015) 126:2726.

52. Marshall ME, Stopforth RJ, Crisp SJ. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. (2017) 8:425. doi: 10.3389/fimmu.2017.00425

53. Harousseau JL, Bouabdallah K, Dueck G, Gribben J, Lugtenburg PJ, et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN Study. Blood. (2016) 128:615.

54. Teeling JL, Mackus WJM, Wiegman LJMJ, Van den Brakel JHN, Reers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. (2006) 177:362–71. doi: 10.4049/jimmunol.177.1.362

55. Marshall ME, Stopforth R, Crisp SJ. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. (2017) 8:1245. doi: 10.3389/fimmu.2017.01245

56. Salles G, Barrett M, Foa R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. (2017) 34:2232–73. doi: 10.1007/s12261-016-1535-8.

57. Kolibaba K, Burke JM, Brooks HD, Maehadevan D, Melear J, Farber CM, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and/or refractory mantle cell lymphoma; results of a Phase II trial. Blood. (2015) 126:3980.

58. Carpenter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. (2001) 1:118–29. doi: 10.1038/35010722

59. Hu B, Jacobs R, Ghosh N. Checkpoint inhibitors Hodgkin lymphoma and non-Hodgkin lymphoma. Curr Hematol Malig Rep. (2018) 13:543–54. doi: 10.1007/s11899-018-0484-4

60. Ansell SM. Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond. Hematol Am Soc Hematol Educ Program. 2017:618–21. doi: 10.1182/ashedu.2017.1.618
61. Savage KJ, Steidl C. Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them. Expert Rev Hematol. (2016) 9:1007–9. doi: 10.1080/17474086.2016.1242404

62. Sun L, Chen LX, Lii H. Checkpoint-mediating immunotherapies in tumor treatment: targets, drugs, and mechanisms. Int Immunopharmacol. (2019) 71:105675. doi: 10.1016/j.intimp.2018.12.006

63. Ansell SM. PD-1 targeted therapy in lymphomas. Br J Haematol. (2018) 182:13.

64. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1b study (KEYNOTE-013). Blood. (2014) 124:290.

65. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. (2017) 129:3419–27. doi: 10.1182/blood-2017-02-765685

66. Silverman E, Kymriah: A sign of more difficult decisions to come. Manag Care. (2018) 27:17.

67. Garon EB, Rizvi NA, Hui RN, Leighl N, Balmanoukian AS, Eder J, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. (2015) 372:2018–28. doi: 10.1056/NEJMoa1508244

68. Ninomiya K, Hotta K. Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opin Biol Ther. (2018) 18:1015–21. doi: 10.1080/14712598.2018.1522300

69. Ding W, Laplant B, Witzig TE, Johnston PB, Colgan JP, Rech KL, et al. PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma. Blood. (2017) 130:4055.

70. Younes A, Santoro A, Shipp M, Zinzani PL, Gutierrez M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1b study (KEYNOTE-013). Blood. (2014) 124:290.

71. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization mechanisms, combinations, and clinical outcome. Front Pharmacol. (2017) 8:561. doi: 10.3389/fphar.2017.00561

72. Ishida Y, Agata Y, Shihabara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. (1992) 11:3887–95. doi: 10.1002/j.1460-2075.1992.tb05481.x

73. Matsuki E, Younes A. Checkpoint inhibitors and other immune therapies mechanism, combinations, and clinical outcome. Front Pharmacol. (2017) 8:561. doi: 10.3389/fphar.2017.00561

74. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Distinct kinetics to CD28 and CTLA-4 receptors. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but different kinetics to CD28 and CTLA-4 receptors. Immunity. (1994) 1:793–801. doi: 10.1016/0178-4435(94)80021-9

75. Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. (2017) 7:5532. doi: 10.1038/s41598-017-06002-8

76. Khouri IF, Fernandez Curbelo I, Turturov F, Jabbour EJ, Milon DR, Bassett JR, et al. Iplimunubam plus lenalidomide after allogeneic and autologous stem cell transplantation for patients with lymphoid malignancies. Clin Cancer Res. (2018) 24:1011–8. doi: 10.1158/1078-0432.CCR-17-2777

77. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. (2015) 124:290. doi: 10.1016/j.ah品位ume.2014.08.003

78. Szabolcs SM, Smolowski P. Immune checkpoint inhibitors to treat malignant lymphomas. J Immunol Res. (2018) 2018:1982423. doi: 10.1155/2018/1982423

79. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Hyo PJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. (2017) 7:5532. doi: 10.1038/s41598-017-06002-8

80. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multikobort, single-arm Phase 2 trial. Lancet Oncol. (2016) 17:1283–94. doi: 10.1016/S1470-2045(16)30167-X

81. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib study. J Clin Oncol. (2016) 34:2698–704. doi: 10.1200/JCO.2015.65.9789
relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure: data from the dose escalation part of the study. Blood. (2017) 130:1522.

10. Xu L, Wang S, Li J, Li B. CD47/SIRPα blocking enhances CD19/CD79b-specific T cell engagement antibody-mediated lysis of B cell malignancies. Biochim Biophys Res Commun. (2019) 509:739–45. doi: 10.1016/j.bbrc.2018.12.175.

11. Kaplan JR, Grishenko M, Giles FJ, Blinatumomab for the treatment of acute lymphoblastic leukemia. Invest New Drugs. (2015) 33:1271–9. doi: 10.1007/s10637-015-0289-4.

12. Johnson SA, Pleiman CM, Pao L, Schneringer J, Hippen K, Cambier JC. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ signaling in mature B cells. J Biol Chem. (2002) 277:18126–34. doi: 10.1074/jbc.M200235200.

13. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR. Blood. (2011) 117:4542–51. doi: 10.1182/blood-2010-09-306449.

14. Rader C. DARTs take aim at BiTEs. Blood. (2011) 117:4403–4. doi: 10.1182/blood-2011-02-337691.

15. Goebeler ME, Knop S, Viardot V, Popp MS, Einsele H, et al. Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a Phase I study. J Clin Oncol. (2016) 34:1104–10. doi: 10.1200/JCO.2014.59.1586.

16. Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. (2016) 127:1410–6. doi: 10.1182/blood-2015-06-613830.

17. Siddqui T, Rosen ST. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation. Oncology. (2015) 29:299–308.

18. Rhodes J, Landsburg DJ. Small-molecule inhibitors for the treatment of diffuse large B-cell lymphoma. Curr Hematol Rep. (2018) 17:356–6. doi: 10.1007/s11899-018-0467-5.

19. Vanhaesebroeck B, Leeners SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. EMBO J. (1995) 15:4596–603. doi: 10.1002/j.1460-2075.1994.tb06387.x.

20. Krause G, Hassenruck F, Hallek M. Copanlisib for treatment of mantle cell lymphoma, and follicular lymphoma. J Clin Oncol. (2018) 36:7520. doi: 10.1200/JCO.2018.36.15_suppl.7520.

21. Assouline S, Amrein L, Barnerij V, Caplan S, Owen CJ, Hasegawa W, et al. A Phase II clinical trial of the pan PI3K inhibitor, buparlisib, in relapsed/refractory chronic lymphocytic leukemia: a multi-center, international, Phase I study. Blood. (2014) 123:299–302. doi: 10.1182/blood-2013-12-531572.

22. Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline, SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. (2017) 28:2169–70. doi: 10.1093/annonc/mdx289.

23. Dreyling M, Santoro A, Mollica L, Leppa S, Follas GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. J Clin Oncol. (2018) 38:2013–20. doi: 10.1200/JCO.2018.36.15_suppl.2013.

24. Cheson BD, O’Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, et al. Optimal management of adverse events from copanlisib in the treatment of patients with non-Hodgkin lymphomas. Clin Lymphoma Myeloma Leuk. (2019) 19:135–41. doi: 10.1016/j.clml.2018.11.021.

25. Dreyling M, A closer look at copanlisib. Clin Adv Hematol Oncol. (2018) 16:35–7.

26. Gilbert JA. Idealisib: targeting PI3Kdelta in B-cell malignancies. Lancet Oncol. (2014) 15:1018. doi: 10.1016/S1470-2045(14)70052-X.

27. Miller BW, Przeworska D, Clarke RA, Lee K, Nie L, Simpson N, et al. FDA approval: idealisib monoclonal antibody therapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res. (2015) 21:1525–9. doi: 10.1158/1078-0432.CCR-14-2522.

28. Do B, Mace M, Rewinkel A. Idealisib is efficacious for treatment of B-cell malignancies. Am J Health Syst Pharm. (2016) 73:547–55. doi: 10.2146/ajhp150281.

29. Madanat YF, Smith MR, Almasan A, Hill BT. Idealisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. Blood. (2016) 127:6204–6. doi: 10.1182/blood-2016-04-714930.

30. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibitor by idealisib in patients with relapsed indolent lymphoma. N Engl J Med. (2014) 370:1008–18. doi: 10.1056/NEJMoa1314583.
140. Gopal AK, Fanale MA, Moskowitz CH, Shustov AR, Mitra S, Ye W, et al. Phase II study of idelisib, a selective inhibitor of PI3Kdelta, for relapsed/refractory classical Hodgkin lymphoma. *Ann Oncol.* (2017) 28:1057–63. doi: 10.1093/annonc/mdx028

141. Gopal AK, Kalil BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, et al. Idelisib is efficacious in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. *Blood.* (2017) 129:3037–9. doi: 10.1182/blood-2016-12-757740

142. Graf SA, Gopal AK. Idelisib for the treatment of non-Hodgkin lymphoma. *Expert Opin Pharmacother.* (2016) 17:265–74. doi: 10.1517/14656566.2016.1135130

143. Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viadot A, Blum KA, et al. Efficacy and safety of idelisib in patients with relapsed, rituximab– and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a Phase 2 study. *Haematologica.* (2017) 102:e156–9. doi: 10.3324/haematol.2016.151738

144. Williams A, Bologa E, Baran A, Helber M, Moore J, Casulo C, et al. Increased risk of toxicity with novel PI3K delta inhibitor combinations compared with standard use in non-Hodgkin lymphoma patients. *Blood.* (2017) 130:4050.

145. Bender MT, Sanso LM, Narula N, Harvey BG, Caner J, PI3K delta inhibitor pulmonary toxicity. *Am J Respir Crit Care Med.* (2017) 195.

146. Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. *Oncology.* (2017) 37:821–8.

147. Liu D, Marmorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies. *J Hematol Oncol.* (2017) 10:145. doi: 10.1186/s13045-017-0515-2

148. Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmune and B-cell cancer. *J Pharmacol Exp Ther.* (2014) 351:538–48. doi: 10.1124/jpet.114.218164

149. Ma J, Xing W, Coffey G, Dresser K, Lu K, Guo A, et al. Cerdulatinib, a Syk/JAK inhibitor, reduces immune complex-mediated inflammation. *J Pharmacol Exp Ther.* (2013) 345:1017–27. doi: 10.1124/jpet.113.199259

150. Schmidt N, Alloway RR, Sadaka B, Wall G, Shields AR, Woodle ES. A Phase II study of bortezomib in patients with mantle cell lymphoma. *Clin Cancer Res.* (2017) 23:2313–24. doi: 10.1158/1078-0432.CCR-16-1662

151. Guo A, Lu P, Coffey G, Conley P, Pandey A, Wang YL. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. *Oncotarget.* (2017) 8:12953–67. doi: 10.18632/oncotarget.14588

152. Coffey G, Rani A, Betz A, Pak Y, Haberstock-Debic H, Pandey A, et al. The dual Syk/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. *Clin Cancer Res.* (2017) 23:2313–24. doi: 10.1158/1078-0432.CCR-16-1662

153. Flinn IW, Bartlett NL, Blum KA, Ardesha KM, LaCasce AS, Flowers CR, et al. A Phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). *Eur J Cancer.* (2016) 54:11–7. doi: 10.1016/j.ejca.2015.10.005

154. Friedman JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. *Blood.* (2010) 115:2578–85. doi: 10.1182/blood-2009-08-234741

155. Herman SE, Barr PM, Mauley EM, Liu D, Wiestern A, Friedman JW. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. *Leukemia.* (2013) 27:1769–73. doi: 10.1038/leu.2013.37

156. Lam B, Arika Y, Cramlett J, Dong Q, de Jong R, Feher V, et al. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). *Bioorg Med Chem Lett.* (2016) 26:5947–50. doi: 10.1016/j.bmcl.2016.10.087

157. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. *Cell.* (1994) 79:13–21. doi: 10.1016/0092-8674(94)90389-4

158. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. *Physiol Rev.* (2002) 82:373–428. doi: 10.1152/physrev.00027.2001

159. Weathington NM, Mallaupalli RK. Emerging therapies targeting the ubiquitin proteasome system in cancer. *J Clin Invest.* (2014) 124:6–12. doi: 10.1172/JCI71602

160. Herman SE, Barr PM, Mauley EM, Liu D, Wiestern A, Friedman JW. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. *Leukemia.* (2013) 27:1769–73. doi: 10.1038/leu.2013.37

161. Lam B, Arika Y, Cramlett J, Dong Q, de Jong R, Feher V, et al. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK). *Bioorg Med Chem Lett.* (2016) 26:5947–50. doi: 10.1016/j.bmcl.2016.10.087

162. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. *Cell.* (1994) 79:13–21. doi: 10.1016/0092-8674(94)90389-4

163. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway. *Cell.* (1994) 79:13–21. doi: 10.1016/0092-8674(94)90389-4

164. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway. *Cell.* (1994) 79:13–21. doi: 10.1016/0092-8674(94)90389-4
179. Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. *Curr Cancer Drug Targets*. (2004) 4:621–35. doi: 10.2174/156800904332718

180. Smith SM. Clinical development of mTOR inhibitors: a focus on lymphoma. *Rev Recent Clin Trials*. (2008) 3:103–10. doi: 10.2174/157488708780599366

181. Duttweiler, A., Reynolds, S.M., Davison, C.W., Young, L.S., Murray, P.G. Constitutive activation of phosphatidylinositol-3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR. *J Pathol.* (2005) 205:498–506. doi:10.1002/path.1725

182. Hess G. mTOR inhibition in diffuse large B-cell lymphoma: new hope? *Lancet Haematol*. (2016) 3:e302–3. doi:10.1016/S2352-3026(16)30047-3

183. Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, et al. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. *Am J Hematol*. (2017) 92:448–53. doi:10.1002/ajh.24671

184. Haritunians T, Mori A, O’Kelly J, Luong QT, Giles FJ, Koeffler HP. Phase 2 study of everolimus as monotherapy to treat patients with relapsed and refractory classic Hodgkin lymphoma. *Exp Hematol Oncol*. (2018) 7:12. doi: 10.1186/s40164-018-0103-x

185. Schoch LK, Asaania A, Zahurak M, Shanbhag S, Hurtle J, Sawyer K, et al. Pharmacokinetically-targeted dosed everolimus maintenance therapy for advanced renal cell carcinoma. *Transplant Rev*. (2018) 33. doi: 10.1016/j.trre.2018.03.002

186. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, et al. Efficacy of the oral mTORC1 inhibitor everolimus in follicular lymphoma. *Am J Hematol*. (2018) 93:748–53. doi: 10.1002/ajh.25468

187. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. *Transplant Rev*. (2014) 28:126–33. doi:10.1016/j.trre.2014.03.002

188. Aster JC, Longtime JA. Detection of BCL2 rearrangements in follicular lymphoma. *Am J Pathol*. (2002) 160:759–63. doi:10.1006/ajpath.2001.1284

189. Weisenburger DD, Gascoyne RD, Bierman PJ, Shenkier T, Horsman DE, Lynch JC, et al. Clinical significance of the (14;18) and BCL2 overexpression in follicular large cell lymphoma. *Leukemia*. (2000) 36:513–23. doi:10.1038/sj.leu.2401909

190. Monni O, Franssila K, Joensuu H, Knuttila S. BCL2 overexpression in diffuse large B-cell lymphoma. *Leukemia*. (1999) 34:45–52. doi:10.1038/sj.leu.2401890

191. Bcl2 (B cell lymphoma). *Ball Dis Cancer*. (1998) 85:738.

192. Harris MM, Coon Z, Alqaesoomi N, Swords B, Holub JM. Targeting anti-apoptotic Bcl2 proteins with squalostatin-based BH3 domain mimetics. *Org Biomol Chem*. (2016) 14:440–6. doi: 10.1039/C5OB02080H

193. Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies. *Clin Pharmacol Ther.* (2017) 101:89–98. doi:10.1002/cpt.553

194. Adams CM, Clark-Garvey S, Porcu P, Eischen CM. Targeting the Bcl-2 family in B cell lymphoma. *Front Oncol*. (2018) 8:636. doi: 10.3389/fonc.2018.00636

195. Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in *in vitro* and *in vivo* models of B-cell lymphoma. *Blood* (2008) 111:5530–8. doi:10.1182/blood-2007-12-129833

196. Cang S, Iragavarapu C, Savojoj I, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. *J Hematol Oncol*. (2015) 8:129. doi:10.1186/s11045-015-0224-3

197. Stolz C, Hess G, Hahnel PS, Grabellus F, Hoffarth S, Schmid KW, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. *Blood* (2008) 112:3312–21. doi:10.1182/blood-2007-11-124487

198. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. *Clin Cancer Res*. (2018) 24:3967–80. doi: 10.1158/1078-0432.CCR-17-13004

199. Roberts AW, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. *N Engl J Med*. (2016) 374:311–22. doi:10.1056/NEJMoa1513257

200. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*. (2018) 378:1107–20. doi:10.1056/NEJMoa1713976

201. Seymour JF, Mobasher M, Kater AP. Venetoclax-rituximab in chronic lymphocytic leukemia. *N Engl J Med*. (2018) 378:2143–4. doi:10.1056/NEJMoa1513315

202. Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO Phase III study. *J Clin Oncol*. (2019) 37:269–77. doi: 10.1200/JCO.2018.01580

203. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. MURANO trial establishes feasibility of time-limited Venetoclax-Rituximab (VenR) combination therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). *Blood*. (2018) 132:184. doi:10.1182/blood-2018-184

204. Mato AR, Tam CS, Allan JN, Brander DM, Pagel JM, Ujjani CS, et al. Disease and patient characteristics, patterns of care, toxicities, and outcomes of Chronic Lymphocytic Leukemia (CLL) patients treated with venetoclax: a multicenter study of 204 patients. *Blood*. (2017) 130:4315.

205. Davids MS, Gerecitano J, Potluri J, Cerri E, Kim SY, Steinberg M, et al. Integrated safety analysis of venetoclax monotherapy in Chronic Lymphocytic Leukemia (CLL). *Haematologica*. (2016) 101:59.

206. Brander DM, Choi MY, Roberts AW, Ma S, Lash LL, Verduo M, et al. Detailed safety analysis of venetoclax combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia. *Blood*. (2016) 128:2033.
Emerging Agents for Lymphoma B

226. Straus DJ, Hamlin PA, Matasar MJ, Lia Palomba M, Drullinsky PR, Zelenetz AD, Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu SS, Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, Crisci et al. Emerging Agents for Lymphoma B

227. Seo YH. Dual inhibitors against topoisomerases and histone deacetylases. Ganjoo KN, de Vos S, Pohlman BL, Flinn IW, Forero-Torres A, Enas AD, et al. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, and Pfolin in patients with relapsed or refractory diffuse large B-cell lymphoma: results from an expanded Phase I trial. J Clin Oncol (2013) 31:4199–206. doi: 10.1200/JCO.2012.48.3685

228. Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including double expressor lymphoma. Haematologica. (2015) 101:175.

229. Yones A, Flinn IW, Oky Y, Copland A, Tatta A, Lai CJ, et al. A first-in-human, Phase 2, single-arm, single-agent trial of vorinostat in patients with relapsed/refractory diffuse large B-cell lymphoma or multiple myeloma: Blood Genet (2015) 3:e100–9. doi: 10.1016/S2352-3026(18)30018-8

230. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a single-centre, open-label, Phase 2 trial. Lancet Oncol (2017) 18:622–30. doi: 10.1016/S1470-2045(17)30120-0

231. Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer (2018) 9:1773–81. doi: 10.7150/jca.24577

232. Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, et al. Observation study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol (2017) 10:171. doi: 10.1186/s13045-017-0537-5

233. Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer (2018) 9:1773–81. doi: 10.7150/jca.24577

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Crisci, Di Francia, Mele, Vitale, Ronga, De Filippi, Berretta, Rossi and Pinto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.